<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        67-100-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRESIBA FlexTouch 100 U/ml solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN DEGLUDEC
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        U/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        359.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AE06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tresiba<sup>&reg;</sup> is a long-acting basal insulin called insulin degludec. It is used to treat diabetes mellitus in adults, adolescents and children aged 1 year and above. Tresiba<sup>&reg;</sup> helps your body reduce your blood sugar level. It is used for once-daily dosing. On occasions when you cannot follow your regular dosing schedule, you can change the time of dosing because Tresiba<sup>&reg;</sup> has a long blood sugar-lowering effect (see section 3, <em>Flexibility in dosing time</em>). Tresiba<sup>&reg;</sup> can be used with meal-related rapid-acting insulin products.</p><p><strong>&nbsp;</strong></p><p>In type 2 diabetes mellitus, Tresiba<sup>&reg;</sup> may be used in combination with tablets for diabetes or with injectable antidiabetic products other than insulin.</p><p>&nbsp;</p><p>In type 1 diabetes mellitus, Tresiba<sup>&reg;</sup> must always be used in combination with meal-related rapid-acting insulin products.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Tresiba<sup>&reg;</sup></strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to insulin degludec or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Tresiba<sup>&reg;</sup>. Be especially aware of the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar (hypoglycaemia) &ndash; if your blood sugar is too low, follow the guidance for low blood sugar in section 4 <em>Possible side effects.</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood sugar (hyperglycaemia) &ndash; if your blood sugar is too high, follow the guidance for high blood sugar in section 4 <em>Possible side effects.</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Switching from other insulin products &ndash; the insulin dose may need to be changed if you switch from another type, brand or manufacturer of insulin. Talk to your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thiazolidinediones used together with insulin, see <em>Thiazolidinediones</em> below.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye disorder &ndash; fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disorder. If you experience eye problems, talk to your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ensuring you use the right type of insulin &ndash; always check the insulin label before each injection to avoid accidental mix-ups between different strengths of Tresiba<sup>&reg;</sup> as well as other insulin products.</p><p>&nbsp;</p><p>If you have poor eyesight, please see section 3 <em>How to use Tresiba<sup>&reg;</sup>.</em></p><p><em>&nbsp;</em></p><p><strong>Skin changes at the injection site</strong></p><p>The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3 <em>How to use Tresiba</em><sup>&reg;</sup>). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>Tresiba<sup>&reg;</sup> can be used in adolescents and children aged 1 year and above. There is no experience with the use of Tresiba<sup>&reg;</sup> in children below the age of 1 year.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Tresiba<sup>&reg;</sup></strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level &ndash; this may mean your insulin dose has to be changed.</p><p>&nbsp;</p><p>Listed below are the most common medicines which may affect your insulin treatment.</p><p>&nbsp;</p><p><strong>Your blood sugar level may fall (hypoglycaemia) if you take:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines for diabetes (oral and injectable)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sulfonamides &ndash; for infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anabolic steroids &ndash; such as testosterone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta-blockers &ndash; for high blood pressure. They may make it harder to recognise the warning signs of too low blood sugar (see section 4, <em>Warning signs of too low blood sugar</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acetylsalicylic acid (and other salicylates) &ndash; for pain and mild fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monoamine oxidase (MAO) inhibitors &ndash; for depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angiotensin converting enzyme (ACE) inhibitors &ndash; for some heart problems or high blood pressure.</p><p><strong>&nbsp;</strong></p><p><strong>Your blood sugar level may rise (hyperglycaemia) if you take:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; danazol &ndash; for endometriosis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral contraceptives &ndash; birth control pills</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid hormones &ndash; for thyroid problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; growth hormone &ndash; for growth hormone deficiency</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glucocorticoids such as &lsquo;cortisone&rsquo; &ndash; for inflammation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sympathomimetics such as epinephrine (adrenaline), salbutamol or terbutaline &ndash; for asthma</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thiazides &ndash; for high blood pressure or if your body keeps too much water (water retention).</p><p>&nbsp;</p><p><strong>Octreotide and lanreotide</strong> &ndash; used to treat a rare condition involving too much growth hormone (acromegaly). They may increase or decrease your blood sugar level.</p><p>&nbsp;</p><p><strong>Thiazolidinediones </strong>&ndash; oral antidiabetic medicine used to treat type 2 diabetes mellitus. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with thiazolidinediones and insulin experienced the development of heart failure. Inform your doctor immediately if you experience signs of heart failure such as unusual shortness of breath, rapid increase in weight or localised swelling (oedema).</p><p>&nbsp;</p><p>If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>Tresiba<sup>&reg;</sup> with alcohol</strong></p><p>If you drink alcohol, your need for insulin may change. Your blood sugar level may either rise or fall. You should therefore monitor your blood sugar level more often than usual.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes is needed in pregnancy. Avoiding too low blood sugar (hypoglycaemia) is particularly important for the health of your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Having too low or too high blood sugar can affect your ability to drive or use any tools or machines. If your blood sugar is too low or too high, your ability to concentrate or react might be affected. This could be dangerous to yourself or others. Ask your doctor whether you can drive if:</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you often get too low blood sugar</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you find it hard to recognise too low blood sugar.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of Tresiba<sup>&reg;</sup></strong></p><p>Tresiba<sup>&reg;</sup> contains less than 1 mmol sodium (23 mg) per dose. This means that the medicine is essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p>If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help. Get help from a person with good eyesight who is trained to use the FlexTouch<sup>&reg;</sup> pre-filled pen.</p><p>Tresiba<sup>&reg;</sup> in a pre-filled pen is available in two strengths. &lsquo;Tresiba<sup>&reg;</sup> 100 units/ml&rsquo; or &lsquo;Tresiba<sup>&reg;</sup> 200 units/ml&rsquo; is clearly marked on the pen label and packaging. In addition, Tresiba<sup>&reg;</sup> 100 units/ml packaging and label are light green, and Tresiba<sup>&reg;</sup> 200 units/ml packaging and label are dark green with a box highlighting the formulation strength.</p><p>&nbsp;</p><p>For both strengths, the needed dose is dialled in units. The dose steps, however, differ between the two strengths of Tresiba<sup>&reg;</sup>.</p><p><strong>&nbsp;</strong></p><p>The pre-filled pen 100 units/ml can provide a dose of 1&ndash;80 units in one injection in steps of 1 unit. The dose window of the pre-filled pen shows the number of units of insulin to be injected. Do not make any dose re-calculation.</p><p>&nbsp;</p><p><strong>Your doctor will decide together with you: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; how much Tresiba<sup>&reg;</sup> you will need each day</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when to check your blood sugar level and if you need a higher or lower dose.</p><p>&nbsp;</p><p><strong>Flexibility in dosing time</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always follow your doctor&rsquo;s recommendation for dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Tresiba<sup>&reg;</sup> once each day, preferably at the same time every day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On occasions when it is not possible to take Tresiba<sup>&reg;</sup> at the same time of the day, it can be taken at a different time of day. Make sure to have a minimum of 8 hours between the doses. There is no experience with flexibility in dosing time of Tresiba<sup>&reg;</sup> in children and adolescents.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you want to change your usual diet, check with your doctor, pharmacist or nurse first as a change in diet may alter your need for insulin.</p><p>&nbsp;</p><p>Based on your blood sugar level, your doctor may change your dose.</p><p>&nbsp;</p><p>When using other medicines, ask your doctor if your treatment needs to be adjusted.</p><p>&nbsp;</p><p><strong>Use in elderly </strong><strong>(&ge;65 years old)</strong></p><p>Tresiba<sup>&reg;</sup> can be used in elderly, but if you are elderly, you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.</p><p>&nbsp;</p><p><strong>If you have kidney or liver problems</strong></p><p>If you have kidney or liver problems, you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.</p><p>&nbsp;</p><p><strong>Injecting your medicine </strong></p><p>Before you use Tresiba<sup>&reg;</sup> for the first time, your doctor or nurse will show you how to use the pre-filled pen.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the name and strength on the label of the pen to make sure it is Tresiba<sup>&reg;</sup> 100 units/ml.</p><p>&nbsp;</p><p><strong>Do not use Tresiba<sup>&reg;</sup> </strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in insulin infusion pumps</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the pen is damaged or has not been stored correctly (see section 5 <em>How to store Tresiba<sup>&reg;</sup></em>)</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the insulin does not appear clear and colourless.</p><p>&nbsp;</p><p><strong>How to inject</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tresiba<sup>&reg;</sup> is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The best places to inject are the front of your thighs, upper arms or the front of your waist (abdomen).</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change the place within the area where you inject each day to reduce the risk of developing lumps and skin pitting<em> </em>(see section 4).</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always use a new needle for each injection. Re-use of needles may increase the risk of blocked needles leading to inaccurate dosing. Dispose of the needle safely after each use.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use a syringe to remove the solution from the pen to avoid dosing errors and potential overdose.</p><p><strong>&nbsp;</strong></p><p>Detailed instructions for use are provided on the other side of this leaflet.</p><p>&nbsp;</p><p><strong>If you use more Tresiba<sup>&reg;</sup> than you should</strong></p><p>If you use too much insulin, your blood sugar may get too low (hypoglycaemia), see advice in section 4, <em>Too low blood sugar.</em></p><p>&nbsp;</p><p><strong>If you forget to use Tresiba<sup>&reg;</sup></strong></p><p>If you forget a dose, inject the missed dose when discovering the mistake, ensuring a minimum of 8 hours between doses. If you discover that you missed your previous dose when it is time to take your next regular scheduled dose, do not take a double dose but resume your once-daily dosing schedule.</p><p>&nbsp;</p><p><strong>If you stop using Tresiba<sup>&reg;</sup></strong></p><p>Do not stop using your insulin without talking to your doctor. If you stop using your insulin, this could lead to a very high blood sugar level and ketoacidosis (a condition with too much acid in the blood), see advice in section 4, <em>Too high blood sugar.</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Hypoglycaemia (too low blood sugar) may occur very commonly with insulin treatment (may affect more than 1 in 10 people). It can be very serious. If your blood sugar level falls too much, you may become unconscious. Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have symptoms of low blood sugar, take actions to increase your blood sugar level immediately. See advice in <em>Too low blood sugar</em> below.</p><p><u>&nbsp;</u></p><p>If you have <strong>a serious allergic reaction</strong> (seen rarely) to the insulin or any of the ingredients in Tresiba<sup>&reg;</sup>, stop using Tresiba<sup>&reg;</sup> and see a doctor straight away. The signs of a serious allergic reaction are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the local reactions spread to other parts of your body</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you suddenly feel unwell with sweating</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you start being sick (vomiting)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you experience difficulty in breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you experience rapid heartbeat or feeling dizzy.</p><p>&nbsp;</p><p><strong>Skin changes at the injection site:</strong></p><p>If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (<em>may affect up to 1 in 100 people</em>). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes.</p><p>&nbsp;</p><p><strong>Other side effects include:</strong></p><p>&nbsp;</p><p><strong>Common </strong><em>(may affect up to 1 in 10 people)</em></p><p><em>Local reactions:</em> Local reactions at the place you inject yourself may occur. The signs may include: pain, redness, hives, swelling and itching. The reactions usually disappear after a few days. See your doctor if they do not disappear after a few weeks. Stop using Tresiba<sup>&reg;</sup> and see a doctor straight away if the reactions become serious. For more information, see <em>serious allergic reaction</em> above.</p><p>&nbsp;</p><p><strong>Uncommon </strong><em>(may affect up to 1 in 100 people)</em></p><p><em>Swelling around your joints:</em> When you first start using your medicine, your body may keep more water than it should. This causes swelling around your ankles and other joints. This is usually only short-lasting.</p><p>&nbsp;</p><p><strong>Rare </strong><em>(may affect up to 1 in 1,000 people)</em></p><p>This medicine can cause allergic reactions such as hives, swelling of the tongue and lips, diarrhoea, nausea, tiredness and itching.</p><p>&nbsp;</p><p><strong>General effects from diabetes treatment</strong></p><p>&nbsp;</p><p><strong><em>►</em></strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Too low blood sugar (hypoglycaemia)</strong></em></p><p>&nbsp;</p><p><strong>Too low blood sugar may happen if you:</strong></p><p>drink alcohol; use too much insulin; exercise more than usual; eat too little or miss a meal.</p><p>&nbsp;</p><p><strong>Warning signs of too low blood sugar &ndash; these may come on suddenly:</strong></p><p>Headache; slurred speech; fast heartbeat; cold sweat, cool pale skin; feeling sick, feeling very hungry; tremor or feeling nervous or worried; feeling unusually tired, weak and sleepy; feeling confused, difficulty in concentrating; short-lasting changes in your sight.</p><p>&nbsp;</p><p><strong>What to do if you get too low blood sugar</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eat glucose tablets or another high sugar snack, like sweets, biscuits or fruit juice (always carry glucose tablets or a high sugar snack, just in case).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Measure your blood sugar if possible and rest. You may need to measure your blood sugar more than once, as with all basal insulin products improvement from the period of low blood sugar may be delayed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wait until the signs of too low blood sugar have gone or when your blood sugar level has settled. Then carry on with your insulin as usual.</p><p>&nbsp;</p><p><strong>What others need to do if you pass out </strong></p><p>Tell everyone you spend time with that you have diabetes. Tell them what could happen if your blood sugar gets too low, including the risk of passing out.</p><p>&nbsp;</p><p>Let them know that if you pass out, they must:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; turn you on your side</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; get medical help straight away</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>not</strong> give you any food or drink because you may choke.</p><p>&nbsp;</p><p>You may recover more quickly from passing out with an injection of glucagon. This can only be given by someone who knows how to use it.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are given glucagon, you will need sugar or a sugary snack as soon as you come round.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not respond to a glucagon injection, you will have to be treated in a hospital.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If severe low blood sugar is not treated over time, it can cause brain damage. This can be short- or long-lasting. It may even cause death.</p><p>&nbsp;</p><p><strong>Talk to your doctor if:</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your blood sugar got so low that you passed out</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have used an injection of glucagon</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had too low blood sugar a few times recently.</p><p>This is because the dosing or timing of your insulin injections, food or exercise may need to be changed.</p><p>&nbsp;</p><p><strong><em>►</em></strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Too high blood sugar (hyperglycaemia)</strong></em></p><p>&nbsp;</p><p><strong>Too high blood sugar may happen if you:</strong></p><p>eat more or exercise less than usual; drink alcohol; get an infection or a fever; have not used enough insulin; keep using less insulin than you need; forget to use your insulin or stop using insulin without talking to your doctor.</p><p>&nbsp;</p><p><strong>Warning signs of too high blood sugar &ndash; these normally appear gradually:</strong></p><p>Flushed, dry skin; feeling sleepy or tired; dry mouth, fruity (acetone) breath; urinating more often, feeling thirsty; losing your appetite, feeling or being sick (nausea or vomiting).</p><p>These may be signs of a very serious condition called ketoacidosis. This is a build-up of acid in the blood because the body is breaking down fat instead of sugar. If not treated, this could lead to diabetic coma and eventually death.</p><p>&nbsp;</p><p><strong>What to do if you get too high blood sugar</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Test your blood sugar level.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Test your urine for ketones.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Get medical help straight away.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the pen label and carton, after &lsquo;Expiry&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Before first use</strong></p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Keep away from the freezing element. Do not freeze. Keep the cap on the pen in order to protect it from light.</p><p>&nbsp;</p><p><strong>After first opening or if carried as a spare</strong></p><p>You can carry your Tresiba<sup>&reg;</sup> pre-filled pen (FlexTouch<sup>&reg;</sup>) with you and keep it at room temperature (not above 30&deg;C) or in a refrigerator (2&deg;C to 8&deg;C) for up to 8 weeks.</p><p>&nbsp;</p><p>Always keep the cap on the pen when you are not using it in order to protect it from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is insulin degludec. Each ml of solution contains 100 units (U) of insulin degludec. Each pre-filled pen (3 ml) contains 300 units (U) of insulin degludec.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are glycerol, metacresol, phenol, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tresiba® is presented as a clear and colourless solution for injection in a pre-filled pen (300 units per 3 ml).

Pack sizes of 1, 5 and 10 (2 x 5) pre-filled pens of 3 ml. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd</p><p>Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nov-2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تريسيبا<sup>&trade;</sup> عبارة عن إنسولين قاعدي طويل المفعول يُسمى إنسولين ديجلودِك. ويُستخدم لعلاج مرض السكري لدى البالغين والمراهقين والأطفال من عمر سنة واحدة فما فوق. يساعد تريسيبا<sup>&trade;</sup> الجسم على تقليل مستوى السكر في الدم. يُستخدم هذا الإنسولين في جرعة واحدة يومياً. في الحالات التي لا تستطيع فيها الالتزام بجدول الجرعات المنتظمة الخاص بك؛ يمكنك تغيير وقت الجرعة لأن تريسيبا<sup>&trade;</sup> له مفعول مخفض لسكر الدم طويل المدى (انظر القسم 3، <em>المرونة في وقت أخذ الجرعة</em>). يمكن استخدام تريسيبا<sup>&trade;</sup> مع منتجات الإنسولين سريعة المفعول المتعلقة بالوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&lrm;أثناء علاج النوع الثاني من داء السكري، يمكن أيضاً استخدام تريسيبا<sup>&trade;</sup> مع الأدوية المضادة للسكري المتناولة عن طريق الفم أو مع المنتجات المضادة للسكري عن طريق الحقن خلاف الإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&lrm;أثناء علاج النوع الأول من داء السكري، يجب دائماً استخدام تريسيبا<sup>&trade;</sup> مع منتجات الإنسولين سريعة المفعول المرتبطة بالوجبات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام تريسيبا</strong><sup>&trade;</sup></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية<strong> </strong>تجاه إنسولين ديجلودِك أو أي من مكونات هذا الدواء (المسرودة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">ينبغي التحدث مع الطبيب أو الصيدلي أو الممرضة قبل استخدام تريسيبا<sup>&trade;</sup>. ينبغي العلم بالأمور التالية على وجه الخصوص:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة السكر في الدم (هبوط سكر الدم) - في حالة الانخفاض الشديد في نسبة السكر في الدم، اتبع الإرشادات الخاصة بانخفاض السكر في الدم في القسم 4<em> </em><em>الآثار الجانبية المحتملة</em><em>.</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم (ارتفاع سكر الدم) - في حالة الارتفاع الشديد في نسبة السكر في الدم، اتبع الإرشادات الخاصة بارتفاع السكر في الدم في القسم 4<em> </em><em>الآثار الجانبية المحتملة</em><em>.</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغيير من منتجات الإنسولين الطبية الأخرى - قد يلزم تغيير جرعة الإنسولين في حالة التحويل من نوع إنسولين آخر أو علامة تجارية أو شركة مصنعة أخرى للإنسولين. ينبغي استشارة الطبيب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام أدوية ثيازوليدينديون مع الإنسولين، انظر <em>أدوية ثيازوليدينديون</em> أدناه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب العين - قد تؤدي التحسينات السريعة في السيطرة على نسبة السكر في الدم إلى تدهور مؤقت في اضطراب العين السكري. إذا كنت تعاني من مشاكل في العين؛ فينبغي استشارة الطبيب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضمان استخدام النوع المناسب من الإنسولين - احرص دائماً على التحقق من ملصق تعريف الإنسولين قبل كل حقنة لتجنب الخلط بطريق الخطأ بين تريسيبا<sup>&trade;</sup> ومنتجات الإنسولين الأخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كنت تعاني من ضعف الرؤية، يُرجى الاطلاع على القسم 3<em> كيفية استخدام تريسيبا</em><sup>&trade;</sup><em>.</em></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تغيرات جلدية في موضع الحقن</strong></p><p dir="RTL">يجب تغيير موضع الحقن باستمرار للمساعدة في منع حدوث تغييرات في الأنسجة الدهنية تحت الجلد، مثل سماكة الجلد أو انكماش الجلد أو وجود كتل تحت الجلد. قد لا يعمل الإنسولين جيداً إذا تم الحقن في منطقة متكتلة أو منكمشة أو سميكة (انظر القسم 3 <em>كيفية استخدام تريسيبا<sup>&trade;</sup></em>). أخبر طبيبك إذا لاحظت أي تغيرات جلدية في موضع الحقن. أخبر طبيبك إذا كنت تحقن حالياً في هذه المناطق المصابة قبل البدء في الحقن في منطقة مختلفة. قد يطلب منك طبيبك فحص نسبة السكر في الدم عن كثب، وتعديل جرعة الإنسولين أو الأدوية الأخرى المضادة لمرض السكر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يستعمل تريسيبا<sup>&trade;</sup> لعلاج مرض السكري لدى المراهقين والأطفال من عمر سنة. وتجدر الإشارة إلى عدم وجود أي تجارب بشأن استعمال تريسيبا<sup>&trade;</sup> مع الأطفال دون سنة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وتريسيبا</strong><sup>&trade;</sup></p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي أو الممرضة إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى في المستقبل. تؤثر بعض الأدوية في مستوى السكر في الدم - وقد يعني هذا ضرورة تغيير جرعة الإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي الأدوية الأكثر شيوعاً التي قد تؤثر في علاجك بالإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد ينخفض مستوى السكر في الدم (هبوط سكر الدم) إذا أخذت:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لمرض السكري (عن طريق الفم أو الحقن)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلفوناميدات - للعدوى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منشطات بنائية - مثل التيستوستيرون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات البيتا - لارتفاع ضغط الدم. فقد تؤدي إلى صعوبة التعرف على العلامات التحذيرية للانخفاض الشديد في سكر الدم (انظر القسم 4<em> </em><em>العلامات التحذيرية للانخفاض الشديد في سكر الدم</em>)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الأسيتيل ساليسيليك (والساليسيلات الأخرى) - للألم والحمى الخفيفة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثَبِّطَات أُكسيدازِ أُحادِيِّ الأَمين (MAO) - للاكتئاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثَبِّطَات الإِنْزيم المُحَوِّل للأَنْجِيوتَنْسين (ACE) - لبعض مشاكل القلب أو ضغط الدم المرتفع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يرتفع مستوى السكر في الدم (ارتفاع سكر الدم) إذا أخذت:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانازُول - للانْتِباذ البِطَانِيّ الرَحِمِيّ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل عن طريق الفم - حبوب منع الحمل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الدرقية - لمشاكل الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون النمو - لنقص هرمون النمو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية القشرانية السكرية مثل &quot;الكورتيزون&quot; - للاتهاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المحاكيات الودية مثل الإبِينيفرِين (الأدرينالين)، أو السالبوتامول أو التيربوتالين - للربو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية ثيازيدات؛ لعلاج ضغط الدم المرتفع أو في حالة احتفاظ الجسم بكميات كبيرة من الماء (احتباس الماء).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأوكتريوتايد واللانريوتايد</strong> - يستعملان لعلاج حالة نادرة تنطوي على زيادة بالغة في هرمون النمو (ضخامة النهايات). قد يتسببان في زيادة أو نقصان مستوى السكر بالدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية ثيازوليدينديون </strong>- فئة من مضادات السكري الفموية المستخدمة لعلاج النوع الثاني من داء السكري. تعرض بعض المرضى المصابين بالنوع الثاني من داء السكري وأمراض القلب لفترات طويلة أو المصابين بسكتة دماغية سابقاً وعولجوا بأدوية ثيازوليدينديون مع الإنسولين بفشل القلب. أخبر طبيبك على الفور إذا ظهرت عليك علامات قصور القلب، مثل صعوبة في التنفس غير معتادة أو زيادة سريعة في الوزن أو تورم موضعي (وذمة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت أي من الأمور أعلاه تنطبق عليك (أو لست متأكداً)، فاستشر الطبيب أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تريسيبا</strong><sup>&trade;</sup><strong> مع الكحول</strong></p><p dir="RTL">إذا كنت تتناول الكحول؛ فقد يلزم تعديل جرعتك من الإنسولين. وذلك لأن مستوى السكر في الدم لديك إما أن يرتفع وإما أن ينخفض. لذلك يجب عليك مراقبة مستوى السكر في الدم أكثر من المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;إذا كنِت حاملاً أو تظنين أنك قد تكونين حاملاً أو كنِت تخططين لانجاب طفل أو إذا كنِت تُرضعين رضاعة طبيعية، فاستشيري الطبيب أو الصيدلي قبل تناول هذا الدواء. قد يلزم تغيير جرعة الإنسولين أثناء الحمل وبعد الولادة. التحكم الدقيق في مرض السكري مطلوب أثناء الحمل. إن تجنب الانخفاض الشديد في سكر الدم (هبوط سكر الدم) أمر مهم بشكل خاص لصحة الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">إن الزيادة الشديدة أو النقص الشديد في سكر الدم يمكن أن يؤثر في قدرتك على قيادة المركبات أو استخدام أي أدوات أو آلات. في حالة الانخفاض الشديد أو الارتفاع الشديد في سكر الدم، فقد تتأثر قدرتك على التركيز أو التفاعل. ويمكن أن يشكل هذا خطورة على سلامتك أو سلامة الآخرين. استعلم من الطبيب عما إذا كان يمكنك قيادة مركبات في الحالات التالية:</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضك في الغالب للانخفاض الشديد في سكر الدم</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التعرف على حالة الانخفاض الشديد في سكر الدم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة عن بعض المكونات في تريسيبا</strong><sup>&trade;</sup></p><p dir="RTL">تريسيبا<sup>&trade;</sup> يحتوي على أقل من 1 مليمول صوديوم (23 ملجم) لكل جرعة. وهذا يعني أن هذا الدواء &quot;خال من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب استعمال هذا الدواء دوماً كما أخبرك الطبيب تماماً. ويجب استشارة الطبيب أو الصيدلي أو الممرضة في حالة الشك بشأن طريقة استخدامه على الوجه الصحيح.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كنت كفيفا أو ضعيف البصر ولا تستطيع قراءة عداد الجرعة على القلم، فلا تستخدم هذا المنتج الطبي دون مساعدة. احصل على المساعدة من شخص يتمتع ببصر جيد ومدرب على استخدام قلم فلكس تاتش<sup>&trade;</sup> المعبأ مسبقاً.</p><p dir="RTL">يتوفر تريسيبا<sup>&trade;</sup> في قلم معبأ مسبقاً بتركيزين. يتم تحديد المنتج &quot;تريسيبا<sup>&trade;</sup> 100 وحدة/مل&quot; أو &quot;تريسيبا<sup>&trade;</sup> 200 وحدة/مل&quot; بشكل واضح على ملصق القلم وعلى العبوة. وبالإضافة إلى ذلك، فإن ملصق وعبوة تريسيبا<sup>&trade;</sup> 100 وحدة/مل لونهما أخضر فاتح، بينما ملصق وعبوة تريسيبا<sup>&trade;</sup> 200 وحدة/مل لونهما أخضر غامق ويوجد مربع يوضح تركيز المستحضر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وبالنسبة لكلا التركيزين، يتم ضبط الجرعة المطلوبة بالوحدات عن طريق بكرة دوارة. إلا أن الجرعات التدريجية تختلف بين هذين التركيزين من تريسيبا<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يعطي قلم الحقن المعبأ مسبقاً بتركيز 100 وحدة/مل جرعة من 1 إلى 80 وحدة في حقنة واحدة في جرعات تدريجية بمقدار وحدة واحدة. وتعرض نافذة الجرعة بالقلم المعبأ مسبقاً عدد وحدات الإنسولين التي سيتم حقنها. لا تقم بإعادة حساب أي جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سوف يقرر الطبيب معك:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مقدار الجرعة التي سوف تحتاج إليها من تريسيبا<sup>&trade;</sup> كل يوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متى تقوم بفحص مستوى السكر في الدم وهل تحتاج إلى جرعة أكبر أو أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرونة في وقت أخذ الجرعة</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي دائماً اتباع توصيات الطبيب بشأن الجرعة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم تريسيبا<sup>&trade;</sup> مرة واحدة في اليوم ويفضل في وقت واحد كل يوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الحالات التي لا يمكنك فيها أخذ جرعة تريسيبا<sup>&trade;</sup> في الوقت المحدد للجرعة في اليوم، يمكن أخذ الجرعة في وقت آخر من اليوم. يُرجى التأكد من مرور مدة 8 ساعات على الأقل بين كل جرعة والتي تليها. وتجدر الإشارة إلى عدم وجود أي تجارب بشأن المرونة في مواعيد جرعات تريسيبا<sup>&trade;</sup> مع الأطفال والمراهقين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أردت تغيير نظامك الغذائي المعتاد، فينبغي استشارة الطبيب أو الصيدلي أو الممرضة أولاً حيث إن تغيير النظام الغذائي قد يؤدي إلى تغيير الجرعة التي تحتاج إليها من الإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بناءً على نتائج فحص مستوى سكر الدم لديك، قد يقوم الطبيب بتغيير الجرعة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند استخدام أدوية أخرى، استعلم من الطبيب عما إذا كان علاجك يحتاج إلى تعديل أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في كبار السن </strong><strong>(&ge;</strong><strong>65</strong><strong> عاماً)</strong></p><p dir="RTL">يمكن استخدام تريسيبا<sup>&trade;</sup> في كبار السن، ولكن قد يحتاج المريض كبير السن إلى فحص مستوى السكر في الدم بمعدل أكبر. ينبغي استشارة الطبيب بشأن تغيير الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تعاني من مش</strong><strong>ا</strong><strong>كل في الكلى أو الكبد</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى أو الكبد فقد تحتاج إلى فحص مستوى السكر في الدم بمعدل أكبر. ينبغي استشارة الطبيب بشأن تغيير الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حقن الدواء </strong></p><p dir="RTL">قبل استعمال تريسيبا<sup>&trade;</sup> لأول مرة، سيوضح لك الطبيب أو الممرضة كيفية ستخدام قلم الحقن المعبأ مسبقاً.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي التحقق من الاسم والتركيز المطبوعين على ملصق تعريف قلم الحقن للتأكد من أن الدواء الذي تستخدمه هو تريسيبا<sup>&trade;</sup> 100 وحدة/مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استخدام تريسيبا</strong><sup>&trade;</sup><strong> </strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في مضخات حقن الإنسولين</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة تلف القلم أو عدم تخزينه بطريقة صحيحة (انظر القسم 5<em> </em><em>كيفية تخزين دواء تريسيبا</em><sup>&trade;</sup>)</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الإنسولين لا يبدو صاف وعديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية الحقن</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تؤخذ جرعة تريسيبا<sup>&trade;</sup> كحقنة تحت الجلد. لا تحقن في الأوردة ولا في العضل.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفضل أماكن في الجسم للحقن هي الفخذ والجزء العلوي من الذراع ومقدمة الخصر(البطن).</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي تغيير موضع الحقن في مكان أخذ الحقنة كل مرة للحد من خطر حدوث تورمات أو نقر في الجلد (انظر القسم 4).</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب دوماً استخدام إبرة جديدة في كل عملية حقن. إن إعادة استخدام الإبر قد تزيد من مخاطر انسداد الإبر، والتي تؤدي بدورها إلى عدم دقة الجرعة. تخلص من الإبرة بشكل آمن بعد كل استخدام.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم حقنة لإزالة المحلول من القلم، وذلك لتجنب الخطأ في الجرعات أو احتمالية أخذ جرعة زائدة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">التعليمات المفصلة للاستخدام موضحة في الجانب الآخر من هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من تريسيبا</strong><sup>&trade;</sup><strong> عن الجرعة الموصوفة</strong></p><p dir="RTL">في حالة استخدام كمية كبيرة من الإنسولين؛ قد ينخفض سكر الدم انخفاضاً شديداً، يُرجى الاطلاع على الإرشادات الواردة في القسم 4<em> الانخفاض الشديد في سكر الدم.</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة تريسيبا</strong><sup>&trade;</sup></p><p dir="RTL">في حالة نسيان جرعة؛ قم بحقن الجرعة المنسية عند تذكرها، مع التأكد من مرور 8 ساعات بين كل جرعة والتي تليها. وإذا اكتشفت أنك نسيت جرعة مضى وقتها وقد حان وقت جرعة أخرى، فلا تأخذ جرعة مزدوجة، ولكن تابع جدول الجرعات اليومية الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استخدام دواء تريسيبا</strong><sup>&trade;</sup></p><p dir="RTL">لا تتوقف عن استعمال الإنسولين بدون استشارة طبيبك. في حالة التوقف عن أخذ الإنسولين الخاص بك قد يحدث ارتفاع شديد في مستوى السكر في الدم لديك وحالة حماض كيتوني (ارتفاع مستوى الحمض اًرتفاعاً شديداً في الدم)، انظر الإرشادات في القسم 4، <em>الارتفاع الشديد في سكر الدم.</em></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحدث هبوط سكر الدم الشديد (انخفاض سكر الدم الشديد) بشكل شائع جداً أثناء العلاج باستخدام الإنسولين (يمكن أن يظهر هذا الأثر في أكثر من مريض واحد من كل 10 مرضى). ويمكن أن تكون هذه الحالة خطيرة جداً. إذا حدث انخفاض شديد في مستوى سكر الدم لديك؛ فقد تفقد الوعي. قد تسبب حالة هبوط السكر الشديد في الدم تلف المخ وتهدد الحياة. إذا حدث أي عرض من أعراض نقص سكر الدم لديك، فقم على الفور بالتدابير اللازمة لزيادة مستوى السكر في الدم لديك. انظر الإرشادات الواردة في القسم <em>انخفاض</em><em> نسبة ال</em><em>سكر في الدم </em>أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من <strong>حساسية شديدة</strong> (تحدث في حالات نادرة) تجاه الإنسولين أو أي من مكونات تريسيبا<sup>&trade;</sup>، فيجب التوقف عن استخدام تريسيبا<sup>&trade;</sup> واستشارة الطبيب على الفور. علامات الحساسية الخطيرة هي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار ردود الفعل الموضعية إلى أجزاء أخرى من الجسم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور المفاجئ بالإعياء مع التعرق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدء الشعور بالغثيان (الرغبة في التقيؤ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بسرعة نبض القلب أو الشعور بالدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تغيرات جلدية في موضع الحقن</strong></p><p dir="RTL">إذا حقنت الإنسولين في نفس المكان، فقد تتقلص الأنسجة الدهنية في موضع الحقن (الحثل الشحمي) أو تتضخم (التكتل الشحمي) (<em>قد </em><em>يصيب</em><em> حتى شخص واحد من كل 100 شخص</em>). قد يحدث التكتل تحت الجلد أيضاً بسبب تراكم بروتين يسمى النشواني (الداء النشواني الجلدي، ومعدل تكرار حدوث ذلك غير معروف). قد لا يعمل الإنسولين جيداً إذا تم الحقن في منطقة متكتلة أو منكمشة أو سميكة. يجب تغيير موضع الحقن مع كل حقنة للمساعدة في منع هذه التغيرات الجلدية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تشمل الآثار الجانبية الأخرى ما يلي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> <em>(</em><em>قد تصيب حتى شخص واحد من بين </em><em>10</em><em> أشخاص</em><em>)</em></p><p dir="RTL"><em>ردود فعل موضعية:</em> قد تحدث ردود فعل موضعية في مكان الحقن في الجسم. يمكن أن تشمل علامات ردود الفعل هذه ما يلي: ألم، احمرار، شرى، تورم وحكة. عادةً ما تزول ردود الفعل بعد عدة أيام. ينبغي استشارة الطبيب إذا لم تزل هذه الأعراض بعد عدة أسابيع. ينبغي التوقف عن استخدام تريسيبا<sup>&trade;</sup> والذهاب إلى الطبيب مباشرة في حالة تفاقم هذه الأعراض. لمزيد من المعلومات انظر القسم <em>حساسية شديدة</em> أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong><em>)</em><em>قد تصيب حتى شخص واحد من بين </em><em>100</em><em> شخص</em><em>)</em></p><p dir="RTL"><em>تورم حول المفاصل:</em><em> </em>عند البدء في استخدام هذا الدواء، يمكن أن يحتفظ الجسم بكمية من الماء أكبر من القدر المعتاد. ويسبب هذا تورماً حول الكاحلين والمفاصل الأخرى. ويكون هذا العارض مؤقتاً عادةً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة </strong><em>(</em><em>قد تصيب حتى شخص واحد من بين </em><em>1000</em><em> شخص</em><em>)</em></p><p dir="RTL">يمكن أن يسبب هذا الدواء ردود فعل تحسسية مثل الشرى وتورم اللسان والشفتين والإسهال والغثيان والتعب والحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات عامة ناشئة عن علاج الداء السكري</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">►<em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><strong><em>انخفاض نسبة السكر في الدم </em></strong><strong><em>(</em></strong><strong><em>هبوط سكر الدم</em></strong><strong><em>)</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تحدث حالة الانخفاض الشديد في سكر الدم للأسباب التالية:</strong></p><p dir="RTL">شرب الكحول، استخدام جرعات مفرطة من الإنسولين، ممارسة تمارين رياضية بشكل أكثر من المعتاد، الإقلال من الطعام بشكل مفرط أو ترك وجبة غذائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلامات التحذيرية على الانخفاض الشديد في سكر الدم - قد تحدث فجأة:</strong></p><p dir="RTL">الصداع؛ ثقل اللسان؛ سرعة ضربات القلب؛ عرق بارد، بشرة باردة شاحبة؛ شعور بالغثيان، شعور بالجوع الشديد؛ رعشة أو الشعور بالعصبية أو القلق؛ الشعور بالتعب بشكل غير عادي، ضعف ونعاس؛ شعور بالارتباك، صعوبة في التركيز؛ تغيرات في الرؤية لفترة قصيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله في حالة حدوث انخفاض شديد في سكر الدم لديك</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أقراص الجلوكوز أو تناول وجبة خفيفة غنية بالسكر، مثل البسكويت أو الحلويات أو عصير الفاكهة (دائماً احمل في حقيبتك أقراص الجلوكوز أو وجبة خفيفة غنية بالسكر، فقد تحتاج إليها).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي قياس مستوى السكر في الدم وأخذ قسط من الراحة. قد تحتاج إلى قياس مستوى السكر في الدم أكثر من مرة واحدة، لأن التحسُّن من حالة الانخفاض الشديد في سكر الدم قد يستغرق بعض الوقت مع منتجات الإنسولين القاعدي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتظر حتى تزول علامات الانخفاض الشديد في سكر الدم أو حتى يستقر مستوى السكر في الدم لديك. ثم تابع أخذ جرعة الإنسولين كالمعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماذا الذي يجب على الأشخاص المحيطون فعله بك إذا حدثت لك غيبوبة </strong></p><p dir="RTL">أخبر جميع الأشخاص الذين تقضي وقتك معهم بأنك تعاني من مرض السكري. أخبرهم بالأعراض التي يمكن أن تحدث في حالة الانخفاض الشديد في سكر الدم لديك بما في ذلك احتمال دخولك في غيبوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبرهم بأنه في حالة دخولك في غيبوية؛ يجب عليهم القيام بما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحويلك على جنبك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طلب المساعدة الطبية لك على الفور</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>عدم</strong> إعطائك أي طعام أو شراب لأنه قد ينحشر في حلقك ويصيبك بالاختناق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تتعافى بسرعة من الغيبوبة عن طريق أخذ حقنة غلوكاغون. يجب ألا تأخذ هذه الحقنة إلا بواسطة شخص متخصص يعرف كيفية استخدامها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة حقنك بحقنة غلوكاغون؛ فستحتاج إلى أخذ سكر أو تناول مأكولات سكرية بمجرد أن تستعيد وعيك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تحدث لديك استجابة للعلاج بحقنة غلوكاغون، فسيلزم تلقي العلاج في مستشفى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تُعالج حالة الانخفاض الشديد في سكر الدم مع مرور الوقت، فيمكن أن تسبب تلفاً في المخ. قد يكون هذا الأثر قصير المدى أو طويل المدى. وقد تؤدي هذه الحالة إلى الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينبغي استشارة الطبيب في الحالات التالية:</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانخفاض الشديد في سكر الدم لدرجة حدوث غيبوبة</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام حقنة غلوكاغون</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابتك بانخفاض شديد في سكر الدم لعدة مرات مؤخراً.</p><p dir="RTL">وهذا لأن حالتك قد تتطلب تعديل جرعة الإنسولين أو موعد أخذ حقنة الإنسولين أو الوجبات الغذائية أو التمارين الرياضية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>►</strong><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong><em>ارتفاع نسبة السكر في الدم </em></strong><strong><em>(ارتفاع</em></strong><strong><em> </em></strong><strong><em>سكر الدم</em></strong><strong><em>)</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تحدث حالة الارتفاع الشديد في سكر الدم للأسباب التالية:</strong></p><p dir="RTL">الإفراط في الأكل أو الإقلال من ممارسة التمارين الرياضية بشكل غير معتاد؛ شرب الكحول؛ الإصابة بالتهابات أو حمى؛ عدم أخذ كمية كافية من الإنسولين؛ الاستمرار في استخدام جرعات من الإنسولين أقل مما تحتاج إليه؛ نسيان استخدام الإنسولين أو التوقف عن استخدام الإنسولين دون التحدث مع الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلامات التحذيرية للارتفاع الشديد في سكر الدم - تظهر هذه العلامات تدريجياً عادةً:</strong></p><p dir="RTL">نوبات حرارة، جفاف الجلد، الشعور بالنعاس أو التعب؛ جفاف الفم، النفس الفاكهي (أسيتوني)؛ كثرة التبول، الشعور بالعطش؛ فقدان الشهية، الشعور أو الإصابة بالتوعك (الغثيان أو القيء).</p><p dir="RTL">قد تكون هذه أعراض حالة خطيرة جداً تُسمى الحماض الكيتوني. وهذه الحالة عبارة عن تراكم أحماض في الدم لأن الجسم يقوم بتكسير الدهون بدلاً من السكر. وإذا لم تُعالج هذه الحالة؛ فقد تحدث غيبوبة سكر وتؤدي إلى الوفاة في نهاية الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله في حالة حدوث ارتفاع شديد في سكر الدم لديك</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قياس مستوى السكر في الدم لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص الكيتونات في البول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طلب المساعدة الطبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة إصابتك بأي آثار جانبية، استشر الطبيب أو الصيدلي أو الممرضة. يشمل هذا أية آثار جانبية محتملة غير واردة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على ملصق قلم الحقن والعلبة الكرتونية بعد كلمة &quot;Expiry&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل الاستخدام لأول مرة</strong></p><p dir="RTL">يُخزن الدواء في الثلاجة (عند درجة حرارة 2 إلى 8 درجات مئوية). يُحفظ الدواء بعيداً عن وحدة التجميد. يُراعى عدم التجميد. أبقِ الغطاء على قلم الحقن لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعد فتح قلم الحقن لأول مرة أو في حالة حمله كاحتياطي</strong></p><p dir="RTL">يمكنك حمل قلم الحقن تريسيبا<sup>&trade;</sup> المعبأ مسبقاً (فلكس تاتش<sup>&trade;</sup>) معك والاحتفاظ به في درجة حرارة الغرفة (لا تزيد على 30 درجة مئوية) أو في الثلاجة (عند درجة حرارة 2 إلى 8 درجات مئوية) لمدة تصل إلى 8 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دائماً على وضع غطاء قلم الحقن على قلم الحقن في حال عدم استخدام القلم، وذلك لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إنسولين ديجلودِك. يحتوي كل مل من المحلول على 100 وحدة من إنسولين ديجلودِك. يحتوي كل قلم حقن معبأ مسبقاً (3 مل) على 300 وحدة من إنسولين ديجلودِك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: جليسرول، ميتاكراسول، فينول، أسيتات زنك، حمض هيدروكلوريك وهيدروكسيد الصوديوم (لضبط درجة الحموضة) وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تريسيبا<sup>&trade;</sup> عبارة عن محلول صافٍ عديم اللون للحقن في قلم معبأ مسبقاً (300 وحدة لكل 3 مل).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات هي قلم واحد أو 5 أقلام أو 10 (2&times;5) أقلام معبأة مسبقاً بكمية 3 مل. قد &rlm;لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd, Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر-2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tresiba 100 units/mL solution for injection in pre-filled pen 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tresiba 100 units/mL solution for injection in pre-filled pen
One pre-filled pen contains 300 units of insulin degludec in 3 mL solution.
1 mL solution contains 100 units insulin degludec* (equivalent to 3.66 mg insulin degludec).

*Produced in Saccharomyces cerevisiae by recombinant DNA technology. For the full list of excipients, see section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tresiba 100 units/mL solution for injection in pre-filled pen Solution for injection (FlexTouch).

Clear, colourless, neutral solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>This medicinal product is a basal insulin for once-daily subcutaneous administration at any time of the day, preferably at the same time every day.</p><p>&nbsp;</p><p>The potency of insulin analogues, including insulin degludec, is expressed in units. One (1) unit of insulin degludec corresponds to 1 international unit of human insulin, 1 unit of insulin glargine (100 units/mL), or 1 unit of insulin detemir.</p><p>&nbsp;</p><p>In patients with type 2 diabetes mellitus, this medicinal product can be administered alone or in any combination with oral antidiabetic medicinal products, GLP-1 receptor agonists and bolus insulin (see section 5.1).</p><p>&nbsp;</p><p>In type 1 diabetes mellitus, Tresiba must be combined with short-/rapid-acting insulin to cover mealtime insulin requirements.</p><p>&nbsp;</p><p>Tresiba is to be dosed in accordance with the individual patient&rsquo;s needs. It is recommended to optimise glycaemic control via dose adjustment based on fasting plasma glucose.</p><p>&nbsp;</p><p>Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Tresiba 100 units/mL and Tresiba 200 units/mL solution for injection in a pre-filled pen</u></em></p><p>Tresiba is available in two strengths. For both, the needed dose is dialled in units. The dose steps, however, differ between the two strengths of the medicinal product.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With Tresiba 100 units/mL a dose of 1&ndash;80 units per injection, in steps of 1 unit, can be administered.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With Tresiba 200 units/mL a dose of 2&ndash;160 units per injection, in steps of 2 units, can be administered. The dose is provided in half the volume of 100 units/mL basal insulin products.</p><p>The dose counter shows the number of units regardless of strength and <strong>no </strong>dose conversion should be done when transferring a patient to a new strength.</p><p>&nbsp;</p><p><em><u>Flexibility in dosing time</u></em></p><p>On occasions when administration at the same time of the day is not possible, Tresiba allows for flexibility in the timing of insulin administration (see section 5.1). A minimum of 8 hours between injections should always be ensured. There is no clinical experience with flexibility in dosing time of Tresiba in children and adolescents.</p><p>&nbsp;</p><p>Patients who forget a dose are advised to take it upon discovery and then resume their usual once-daily dosing schedule.</p><p>&nbsp;</p><p><em><u>Initiation</u></em></p><p><em>Patients with type 2 diabetes mellitus</em></p><p>The recommended daily starting dose is 10 units followed by individual dosage adjustments.</p><p>&nbsp;</p><p><em>Patients with type 1 diabetes mellitus</em></p><p>Tresiba is to be used once daily with mealtime insulin and requires subsequent individual dosage adjustments.</p><p>&nbsp;</p><p><em><u>Transfer from other insulin medicinal products</u></em></p><p>Close glucose monitoring is recommended during the transfer and in the following weeks. Doses and timing of concurrent rapid-acting or short-acting insulin products or other concomitant antidiabetic treatment may need to be adjusted.</p><p>&nbsp;</p><p><em>Patients with type 2 diabetes mellitus</em></p><p>For patients with type 2 diabetes taking once-daily basal, basal-bolus, premix or self-mixed insulin therapy, changing the basal insulin to Tresiba can be done unit-to-unit based on the previous basal insulin dose followed by individual dosage adjustments.</p><p>&nbsp;</p><p>A dose reduction of 20% based on the previous basal insulin dose followed by individual dosage adjustments should be considered when</p><p>-&nbsp; transferring to Tresiba from twice-daily basal insulin</p><p>-&nbsp; transferring to Tresiba from insulin glargine (300 units/mL)</p><p>&nbsp;</p><p><em>Patients with type 1 diabetes mellitus</em></p><p>For patients with type 1 diabetes a dose reduction of 20% based on the previous basal insulin dose or basal component of a continuous subcutaneous insulin infusion regimen should be considered with subsequent individual dosage adjustments based on the glycaemic response.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Use of Tresiba in combination with GLP-1 receptor agonists in patients with type 2 diabetes mellitus</u></em></p><p><em>&nbsp;</em></p><p>When adding Tresiba to GLP-1 receptor agonists, the recommended daily starting dose is 10 units followed by individual dosage adjustments.</p><p>&nbsp;</p><p>When adding GLP-1 receptor agonists to Tresiba, it is recommended to reduce the dose of Tresiba by 20% to minimise the risk of hypoglycaemia. Subsequently, dosage should be adjusted individually.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em><u>Elderly (&ge;65 years old)</u></em></p><p>Tresiba can be used in elderly. Glucose monitoring is to be intensified and the insulin dose adjusted on an individual basis (see section 5.2).</p><p>&nbsp;</p><p><em><u>Renal and hepatic impairment</u></em></p><p>Tresiba can be used in renal and hepatic impaired patients. Glucose monitoring is to be intensified and the insulin dose adjusted on an individual basis (see section 5.2).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>There is no clinical experience with the use of this medicinal product in children below the age of 1 year. This medicinal product can be used in adolescents and children from the age of 1 year (see</p><p>section 5.1). When changing basal insulin to Tresiba, dose reduction of basal and bolus insulin needs to be considered on an individual basis in order to minimise the risk of hypoglycaemia (see section 4.4).</p><p>&nbsp;</p><p><u>Method of administration</u> Subcutaneous use only.</p><p>&nbsp;</p><p>Tresiba must not be administered intravenously as it may result in severe hypoglycaemia.</p><p>This medicinal product must not be administered intramuscularly as it may change the absorption. This medicinal product must not be used in insulin infusion pumps.</p><p>Tresiba must not be drawn from the cartridge of the pre-filled pen into a syringe (see section 4.4).</p><p>&nbsp;</p><p>Tresiba is administered subcutaneously by injection in the thigh, the upper arm or the abdominal wall. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p>Patients should be instructed to always use a new needle. The re-use of insulin pen needles increases the risk of blocked needles, which may cause under- or overdosing. In the event of blocked needles, patients must follow the instructions described in the instructions for use accompanying the package leaflet (see section 6.6).</p><p>&nbsp;</p><p><u>Tresiba 100 units/mL and Tresiba 200 units/mL solution for injection in a pre-filled pen</u></p><p>Tresiba comes in a pre-filled pen (FlexTouch) designed to be used with NovoFine or NovoTwist injection needles.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The 100 units/mL pre-filled pen delivers 1&ndash;80 units in steps of 1 unit.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The 200 units/mL pre-filled pen delivers 2&ndash;160 units in steps of 2 units.</p><p>&nbsp;</p><p><u>Tresiba 100 units/mL solution for injection in a cartridge</u></p><p>Tresiba comes in a cartridge (Penfill) designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist injection needles.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypoglycaemia</u></p><p>Omission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia.</p><p>&nbsp;</p><p>Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement (see sections 4.5, 4.8 and 4.9).</p><p>In children, care should be taken to match insulin doses (especially in basal-bolus regimens) with food intake and physical activities in order to minimise the risk of hypoglycaemia.</p><p>Patients whose blood glucose control is greatly improved (e.g. by intensified insulin therapy) may experience a change in their usual warning symptoms of hypoglycaemia and must be advised accordingly. Usual warning symptoms may disappear in patients with long-standing diabetes.</p><p>&nbsp;</p><p>Concomitant illness, especially infections and fever, usually increases the patient&#39;s insulin requirement. Concomitant diseases in the kidney, liver or diseases affecting the adrenal, pituitary or thyroid gland may require changes in the insulin dose.</p><p>&nbsp;</p><p>As with other basal insulin products, the prolonged effect of Tresiba may delay recovery from hypoglycaemia.</p><p>&nbsp;</p><p><u>Hyperglycaemia</u></p><p>Administration of rapid-acting insulin is recommended in situations with severe hyperglycaemia.</p><p>&nbsp;</p><p>Inadequate dosing and/or discontinuation of treatment in patients requiring insulin may lead to hyperglycaemia and potentially to diabetic ketoacidosis. Furthermore, concomitant illness, especially infections, may lead to hyperglycaemia and thereby cause an increased insulin requirement.</p><p>&nbsp;</p><p>Usually, the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, and loss of appetite as well as acetone odour of breath. In type 1 diabetes mellitus, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal.</p><p>&nbsp;</p><p><u>Transfer from other insulin medicinal products</u></p><p>Transferring a patient to another type, brand or manufacturer of insulin must be done under medical supervision and may result in the need for a change in dosage.</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site from an affected to an unaffected area, and dose adjustment of antidiabetic medications may be considered.</p><p>&nbsp;</p><p><u>Combination of pioglitazone and insulin medicinal products</u></p><p>Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac failure. This should be kept in mind if treatment with the combination of pioglitazone and Tresiba is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.</p><p>&nbsp;</p><p><u>Eye disorder</u></p><p>Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.</p><p>&nbsp;</p><p><u>Avoidance of medication errors</u></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect id="docshape2"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:35.4pt;margin-top:663.95pt;width:.7pt;height:63.25pt;z-index:15728640;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 fillcolor="black" stroked="f">
 <w:wrap anchorx="page" anchory="page"/>
</v:rect><![endif]--><img width="1" height="85" src="file:///C:/Users/abbd/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between the two different strengths of Tresiba as well as other insulin products.</p><p>&nbsp;</p><p>Patients must visually verify the dialled units on the dose counter of the pen. Therefore, the requirement for patients to self-inject is that they can read the dose counter on the pen. Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.</p><p>&nbsp;</p><p>To avoid dosing errors and potential overdose, patients and healthcare professionals should never use a syringe to draw the medicinal product from the cartridge in the pre-filled pen.</p><p>In the event of blocked needles, patients must follow the instructions described in the instructions for use accompanying the package leaflet (see section 6.6).</p><p>&nbsp;</p><p><u>Insulin antibodies</u></p><p>Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially</p><p>&lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>A number of medicinal products are known to interact with glucose metabolism. <u>The following substances may reduce the insulin requirement</u></p><p>Oral antidiabetic medicinal products, GLP-1 receptor agonists, monoamine oxidase inhibitors</p><p>(MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulfonamides.</p><p>&nbsp;</p><p><u>The following substances may increase the insulin requirement</u></p><p>Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.</p><p>&nbsp;</p><p>Beta-blockers may mask the symptoms of hypoglycaemia. Octreotide/lanreotide may either increase or decrease the insulin requirement. Alcohol may intensify or reduce the hypoglycaemic effect of insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The use of Tresiba in pregnant women with diabetes has been investigated in an interventional trial and as part of a prospective non-interventional study (see section 5.1). The use of Tresiba during pregnancy has not shown any foetal malformation or feto/neonatal toxicity. The treatment with Tresiba may be considered during pregnancy, if clinically needed.</p><p>&nbsp;</p><p>Animal reproduction studies have not revealed any difference between insulin degludec and human insulin regarding embryotoxicity and teratogenicity.</p><p>&nbsp;</p><p>In general, intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually decrease in the first trimester and increase subsequently during the second and third trimesters. After delivery, insulin requirements usually return rapidly to pre-pregnancy values.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There is no clinical experience with Tresiba during breast-feeding. In rats, insulin degludec was secreted in milk; the concentration in milk was lower than in plasma.</p><p>&nbsp;</p><p>It is unknown whether insulin degludec is excreted in human milk. No metabolic effects are anticipated in the breast-fed newborn/infant.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Animal reproduction studies with insulin degludec have not revealed any adverse effects on fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product has no or negligible influence on the ability to drive and use machines. However, the patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).</p><p>&nbsp;</p><p>Patients must be advised to take precautions to avoid hypoglycaemia while driving. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most frequently reported adverse reaction during treatment is hypoglycaemia (see section</p><p>&lsquo;Description of selected adverse reactions&rsquo; below).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions listed below are based on clinical trial data and classified according to MedDRA System Organ Class. Frequency categories are defined according to the following convention: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to</p><p>&lt;1/1,000); very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypoglycaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lipodystrophy</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Cutaneous amyloidosis<sup>&dagger;</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Injection site reactions</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Peripheral oedema</p></td></tr></tbody></table><p>&dagger; ADR from postmarketing sources.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em><u>Immune system disorders</u></em></p><p>With insulin preparations, allergic reactions may occur. Immediate-type allergic reactions to either insulin itself or the excipients may potentially be life-threatening.</p><p>&nbsp;</p><p>With Tresiba, hypersensitivity (manifested with swelling of tongue and lips, diarrhoea, nausea, tiredness and itching) and urticaria were reported rarely.</p><p>&nbsp;</p><p><em><u>Hypoglycaemia</u></em></p><p>Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.</p><p>&nbsp;</p><p><em><u>Skin and subcutaneous tissue disorders</u></em></p><p>Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).</p><p>&nbsp;</p><p><em><u>Injection site reactions</u></em></p><p>Injection site reactions (including injection site haematoma, pain, haemorrhage, erythema, nodules, swelling, discolouration, pruritus, warmth and injection site mass) occurred in patients treated with Tresiba. These reactions are usually mild and transitory and they normally disappear during continued treatment.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Tresiba has been administered to children and adolescents up to 18 years of age for the investigation of pharmacokinetic properties (see section 5.2). Safety and efficacy have been demonstrated in a long term trial in children aged 1 to less than 18 years. The frequency, type and severity of adverse reactions in the paediatric population do not indicate differences to the experience in the general diabetes population (see section 5.1).</p><p>&nbsp;</p><p><u>Other special populations</u></p><p>Based on results from clinical trials, the frequency, type and severity of adverse reactions observed in elderly and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.</p><p><u>Please report adverse drug events to: </u></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A specific overdose for insulin cannot be defined. However, hypoglycaemia may develop over sequential stages if a patient is dosed with more insulin than required:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild hypoglycaemic episodes can be treated by oral administration of glucose or other products containing sugar. It is therefore recommended that the patient always carries glucose-containing products.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe hypoglycaemic episodes, where the patient is not able to treat himself, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional. Glucose must be given intravenously if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes. Insulins and analogues for injection, long-acting. ATC code: A10AE06.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin.</p><p>&nbsp;</p><p>The blood glucose-lowering effect of insulin is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Tresiba is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading to a flat and stable glucose-lowering effect of Tresiba (see figure 1). During a period of 24 hours with once-daily treatment, the glucose-lowering effect of Tresiba, in contrast to insulin glargine, was evenly distributed between the first and second 12 hours (AUCGIR,0-12h,SS/AUCGIR,total,SS = 0.5).</p><p><img alt="" width="200" height="141" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAj0AAAGUCAYAAADeapO6AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAGnXSURBVHhe7Z13uB5F3f79523+pEpVVF4RC4gKghSlCyhSFEvABgIKiFQRQicQkJJgEtIgvUAAaSKhN2khCUmAEJr0EPJS0isIzi+fybkfh3Wfc85zztkn5zl7f65rrt2dnZ3d/W6Ze2e+M/uRYIwxxhhTAix6jDHGGFMKLHqMMcYYUwoseowxxhhTCix6jDHGGFMKLHqMMcYYUwoseowxxhhTCix6jDHGGFMKLHqMMcYYUwoseowxxhhTCjqd6PnnP//ZNBfCu+++G/7xj3/EuA8++KCyLk1jjDHGGNMaOp3oef/998N7770XxQ5CR6IHWE7FjzHGGGNMa+k0ogexQ1CtDvMSOJqmwRhjjDGmFjqN6EHIUMODwAEJH2p6VOsjwZPW/hhjjDHGtIZOI3okbERW1CCAli9fbrFjjDHGmDbRaUQPtTywePHicPfdd4dBgwaFPn36hHHjxoWZM2dGsaPmr5YEkjHGGGPqR1omd2Y6jeihp9Y777wTTjjhhLD++uuHrbfeOmyzzTZh8803D1deeWVMg+hBHFHjkzZ5Mb9w4cIwd+7cMH/+fAcHBwcHB4eCwoIFC2KgzGa6ZMmSWIZTRnd2Oo3ogQsvvDCst9564ZRTTgkTJ04M06ZNC/fdd1949tlnKzU9CB0JHqbw4osvhgEDBoRRo0aF0aNHOzg4ODg4OBQUxowZE6cjRowIw4cPD9ddd10si9Vi05npNKJnzpw5Ydtttw377LNPVIwpCB5EzrJlyyrCJ3V6njBhQrjkkkvCrFmzYnjjjTccHBwcHBwcCgq4nVDePvroo+Giiy6KZbFremrg+eefD+uss04YOXJkmDp1arjmmmtiLc+8efMqggfxk1ahSfRg9MsvvzzOG2OMMaY+vPXWW1H0qHKis9NpRM9dd90V1lxzzbDffvtFP57VVlstbLDBBuGQQw4Jf//736MxVQMk4YMQYv6BBx6IYglI5+Dg4ODg4FBcoAxG6Pzf//1f+NOf/hTLX5Y7O51G9NAu+IlPfCJsvPHGYezYseGZZ56JTs3/9V//Fbp37x79d1LnZQI1QfgBHXHEEbGnl9B6BwcHBwcHh2IC0MTVt2/fuOzmrRq45ZZbwhprrBEuuOCCppiVxtx0003D/vvvH9sQMSi+POrBRS0PtT3U9AwdOrRpK2OMMcYUiUSPa3rayJNPPhnWWmut0L9//6aYEAXNl7/85bDrrrt+SPRQ46Nu6zB58uQwbNiwOG+MMcaYYrHoaSf03tpxxx3DHnvsEQUO4gYhs/rqq8fmK8bhAdX0qLYHJk2aFLvOQSMY3RhjjGlkLHo6AJqoGJiQmp1DDz00zm+22Wbh4YcfjuvlPKUgIUQtEX5AxhhjjCkei552snTp0lh7c/3118eanYMOOigOUkh3dI3Po15b1PAsWrQoGnjGjBnR0bl3795NORljjDGmSCx62glihpocQAAhdOSzg9hRNzkF4lhPbQ//5xoyZEhMa4wxxphiseipMxhXPj3UBmmcHmOMMcYUi0VPHaGmhxoeanpoEuM/XXJkNsYYY0yxWPTUGYSPmr8ef/zx+LNRaASjG2OMMY2MRU8dQfDg88OUAQzPO++8yojMFj3GGGNMsVj01BEMiyMzU8b34WejAwYMaFprjDHGmCKx6KkzaW+v6dOnu3nLGGOMqRMWPXUEw+LPQ+8txE/qyGzRY4wxxhSLRU+dQfRosMJHHnkkjBkzJsZb9BhjjDHFYtFTRzAsoofp22+/HUdjvuyyy5rWGmOMMaZILHrqDP481PLMnz8/+vMMGjSoaY0xxhhjiqSUoufBBx8MRx11VNhkk03CRz7ykUpgmfjx48c3pex40nF6pk2bVmneMsYYY0yxlEr0MBjgXnvtFQUO09NOOy1cdNFFHwrEr7XWWmHrrbeO6TsSDEtQ763HHnvMv6Ewxhhj6kRpRA8/96Qmh2lrqDV9a8Cw1PJI9EyaNMm9t4wxxpg6UQrRQ40NtTe11ty88847scaH5rCOQo7MCxYsiD49AwcObFpjjDHGmCIpheihGautTVVsh59PR0EtDz8bfeutt6ITs4xujDHGmGIphejpTCB4GKcHHnrooTB8+PA43whGN8YYYxqZUoqeVd17C+EDU6ZMqfyGwhhjjDHFUirRQ1PVquy9BRiXcXpg8uTJFj3GGGNMnSiN6Oksvbeo5SEwIjM+PX369Glaa4wxxpgiKYXoocamM/TekugB8qbnVv/+/eOyMcYYY4qlFKKns/XekiMz4/SoeasRjG6MMcY0MqUQPbWCX09RIHr0Gwp8ejwiszHGGFMfSi168NfJOjJTK4SjcxFgWDVvwfTp0ytd1o0xxhhTLKUVPerFVS0UBcal9xaOzJdccknFp6cRjG6MMcY0MqUVPQibvPF4cDAuUvRQ00MT17x580K/fv38GwpjjDGmTpRW9NArqxod+a+tLBhXBp46daqbt4wxxpg6UVrRg7AZPHhw09KHqZcjM723hg0bFueNMcYYUyylFT0IGwYfZJoGaoCK9umRgfkNhWt6jDHGmPpQWtHD2DtyWs4LRSGfngULFoQrrrgijspsjDHGmOIpreiheYtRmrMU7ciMcWnewuA9evSo/IaiEYxujDHGNDKlFT3NUZQjM4ZdunRprOkBxukZMWJEnDfGGGNMsZRC9Lz44osxpCBs8gLd2Iuq6cGwNG9pgMKJEyfakdkYY4ypE6UQPTRjZZuycGJOfXiyoSj479bixYvj/LRp08Lo0aPjfCMY3RhjjGlkSiF6qL3JDkRId3WEUD1/QwHU8tDEtWTJknDbbbe595YxxhhTJ0ohevLAYRmRk0e1+PaCL8+iRYuigZ966qnw+9//PvTq1atprTHGGGOKpLSipzlqFT2IGYzGP7XomcUyNTrLli2LcaxL0xAP+BCNGjUqzhtjjDGmWEotenBubq8jMyIHPx0JG0SNxI9Ej4QQ86kjMyMyjxw5Ms43gtGNMcaYRqa0oofanNRxORtaiwRMNRA8y5cvr8yrlgcYkVmixxhjjDHFUlrRg7DBabm9NT0Y6+mnnw533XVX3PbWW28Nd955Z7jlllvCq6++GtMgjKjpAWp7NFYP+7MjszHGGFMfSit68kZjFrX69HTv3j12gd9tt93CzjvvHLbbbrvw7W9/u9JjDINS20Mz2Pz582OND47MJ5xwQmVfjWB0Y4wxppEpreihyzo1LXnw49HWgrGOPPLI+KPShx9+ONb6MNLyY489Ft5+++1Ys0P3dAQPYodl+fncf//9YciQIU05GWOMMaZISit6oFu3brGmJQ21jtNDF/Qf/ehHYe+9926K+Rc0a8l5GajtYVkG9l/WjTHGmPpRWtEjcVMttJa5c+eG/fffP+ywww5h3Lhx0Z/n2WefrYgbTQn48aT+PfTeck2PMcYYUx9KK3oQNjRxZaEbey2iBx+dnXbaKXz2s58NW2yxRVhjjTXCpptuGgYOHBgdliV8EDoy7IIFC8K8efNi89bYsWNjXCMY3RhjjGlkSit6cDyuRjVfnzzw17n99tvD3XffHUUMXdC33377sP7664ebb745psF/BzAsgR+Nku6MM84Iffv2rawzxhhjTHGUVvQ8/vjj//Y/LlGLIzO1OFnId+211w7HHHNMxZiq7SFQO/TWW2/FprChQ4fG9cYYY4wpltKKHoQNPa6YpoG4Wpq3UmNJAE2dOjV86lOfir265L/DlBof1foAPj2XX35505IxxhhjiqS0oueoo46qOC3nhdbCCMsYTz20cGw+9thjw2qrrRb9eoA0GFU1Pak4GjFiRJw3xhhjTLGUVvTgt5M3QCF/X69F9NBM9cMf/jB2WT/00EPDN77xjbDmmmuGAw88MMyaNSuKHMboAcSOxBFGxgdIXdYbwejGGGNMI1Na0dNRLF68ODojI3IOP/zwcNhhh8Vu6DNnzozj8uiXE6rtURPXm2++Gfr16xf69OnTlJMxxhhjiqRUoocu6tTkEPK6q7cF1eIgahA5qfEWLlwYa3cQRqxH7LDMlLirr746DBgwoCm1McYYY4qkVKKH5izEDqG5f2/VQtpkBfLZQQwRj7hB5BDPMvH66zqOzPLpaQSjG2OMMY1MqUQP3dT59QSB+Y4AgSORIwHEFKEj0aN44jAuyzBt2rQwevToOG+MMcaYYimF6FE3dLqkS/QwTxzr2gM1OKmQYT5dBqUhIHyo6UEE3XfffWHYsGFNqYwxxhhTJJTD0KVFDz21aNJiqh+Lar7aAIVFgGHl9/PCCy+Ec889t+LI3AhGN8YYYxqZUogewdg8/GiUKaHepKKH5rBbbrklXHHFFZV1xhhjjCmOUokenJep4SE09++tIpFDM0yZMiWMGTMmzhtjjDGmWEolelY1GJYaHoQPTJ48uTI4oTHGGGOKpdSihxqfatC768UXX2xa6hgwrAIgehjI0BhjjDHFU2rRQ+8tBipE/DAV+P2wDkfncePGNcV2DOrVNXv27NCzZ88waNCguGyMMcaYYim96MHPR1ON3cMyAejd1ZE9vDCuxvK59tprw9ChQ5vWGGOMMaZISit6qM1hjB4EDTU9GrsHUtEDim8vEjxyZGZEZo/TY4wxxtSH0ooeanZSn5307+pZ0ZPOtwcMq5GaAdFjR2ZjjDGmPpRW9CBkUj8eBJC6sRclegDRw5/Xgd9Q0MQF6tFljDHGmGIorehhcEKatzRCM4KHJi6au1LRQ9NXR/2cFPDlwcAvvfRS6N69e+jbt2+MbwSjG2OMMY1MaUUPtTz6/xYBHx/iED4sI4oQQ6TpqNGbMSyih1qdhQsXhuuuuy4MGDCgaa0xxhhjiqS0oqc1SAR11B/ZMSxNWzRxwdSpU+3TY4wxxtSJ0ooeanGq0VG9tbJg2GqOzI1gdGOMMaaRKa3ooQkrdWQWxMmfpwgQPQsWLIjzM2bMCFdeeWWcN8YYY0yxlFr0ZEdbRvDg3FyU6MGwNG/h1/Pyyy+HSy+9NPTr169prTHGGGOKpNSiBwdl+evQZR3BQy+uokUPtT2vv/56FD2XXXZZ01pjjDHGFElpRQ9Qs4P/DjU+dEtH9HSU03JzLF++PE4nTpwYRo8eHeeNMcYYUyylFj2gJi2CfHyKcmSmq/rixYvDu+++G2t7ED0jRoxoWmuMMcaYIimF6EHENBckejRfZPMWgkd/WqfL+qhRo+K8McYYY4qlFKJHAw7WEooAw1LDg+iZP39+/NnooEGDKuuMMcYYUxylED21/EqiyC7rNG/pv1szZ84M55xzTkMZ3RhjjGlkSiN62kN7t09B+Ojnok8++WSlecuixxhjjCmWUoge/qvV3AjMzaF/cHUEGJbRmAkIH4/IbIwxxtSPUogewEF58ODBTUutQ39i70jw6dEAhZMnTw5jxoyJ8RY9xhhjTLGURvTgq4NDM4MPIn7ymqxIQzw1O6RD9Kgbe0eAYfXfLX5FgSNzrULMGGOMMW2jNKJHIGromp7trZUG1nekH0+KfHreeuut0KdPH4/IbIwxxtSJ0okewW8nGImZWh0FlokvEgQPTVyAT49HZDbGGGPqQylED81U48ePb1padWBY1fTAY4895sEJjTHGmDpRCtGDXw61OIifVSmAMCwOzBI9U6ZMCSNHjozzxhhjjCmWUoielFUpgDCsHJn56eiNN94YrrjiirjcCEY3xhhjGpnSiZ6UVSGAqOlB+MyePTs6Ml966aVNa4wxxhhTJKUWPSlZAVQUODFrcMI777wzDBkypGmNMcYYY4qk1KKnWrd0BNDjjz9eSE8uRA9NW4Ajs316jDHGmPpQatHDmDwIHMQPU8FvK1inbuwtgcEIclDOovWaV5f1adOmVUZkNsYYY0yxqCwurejh7+uaUrujeALg59Ocr8+7774bRQy+Ohhu6tSpceydW2+9NY66TBzNWQTSEdiGcMstt8RRmaERjG6MMcY0MqUVPdTm8F8tBA01PfyigpGYIRU9oPg8JGbgueeeC5tvvnncdocddgivvvpqjKc5C6MidNS0NWvWrHD++efbkdkYY4ypE6UVPdTspD47NG9J6GRFTzqfZdmyZVH4IGiOPvro8MlPfjJsuummYc899wxvvPFGbPJSTZDG6MHAbPPXv/61UtNjjDHGmGIprehByKR+PAggfjIKtYgehAzQpLXhhhuGHj16hO985zthxx13jEYF0iCKMCzzqu1hcEKPyGyMMcbUh9KKHrql07yl/24heGjiorkrFT00fVErVA2M9dprr4Xtt98+7L///uH5558Pu+22W2zeevPNNytCBxA7iB+B/8+IESOalowxxhhTJKUVPdTypH9bx8eHOIQPy4gixBBpWhq35+yzzw7rrrtuuOeee6Kw2XnnncN2220Xm7cQPHJeZh7jzps3L8ycOTPcfvvtYejQoU25GGOMMaZISit6WoNEkHp15cFYO9QSHXPMMXEZX53dd9897LTTTlHcIHTk7KxmrenTp0dfnjPPPDMMHDgwxjWC0Y0xxphGxqInB2p4WsvPfvazsPbaa4c//vGPlX9p0Wy25ZZbhksuuSQaFudl1fhg3CVLlsTu7Pfee2/l31vGGGOMKZZSix6cl/HZSYN8elrLr371q+jDg/Py3nvvHeep+dl4443DLrvsEh555JGYbtGiRVH0pAMYTpw40eP0GGOMMXWitKKH2hz58+SF1sKPQ19++eXwyiuvRIfmGTNmRKfmrbbaKjZ9Uaujbur49RCWLl0at0X0uPeWMcYYUx9KK3oQNjgvt7emB3+dlDlz5kTRs80228TeW5CO06MeXMTdcccd7r1ljDHG1InSip7muqHX4tMjMaPam4ULF4Y+ffqE3r17h7lz58Y4BjBUbY8CPbvOOeccj8hsjDHG1InSip7BgwfHmp08mvvtRHvAsNT0yLH5L3/5S6XLeiMY3RhjjGlkSit6gO7o1OqkQX9YLwIMS9MWwod5fH7Gjh3btNYYY4wxRVJa0SNxUy0Uhfx6qO2ZMGFCGD58eIxvBKMbY4wxjUxpRQ/ChiauLHRjL0r0YFhEjwYrnDx5sn84aowxxtSJ0ooe/Vw0j2q+Pu0Fw2qsHkZ5Pumkk0KvXr3iOuKMMcYYUxylFT2IDrqn51GUIzNgXAQOTVx//etfw+WXX960xhhjjDFFUlrRg7DhdxFM00Bc0T49dGGHRx99NIwcOTLOG2OMMaZYSit6+HO6nJbzQhFQw8M4PjRx4dfDiMwenNAYY4ypD6UVPfjt5A1QyJ/VixI9gHE1ivPUqVMrv6FoBKMbY4wxjUwpRE97HZM7yrGZmh7+xYWBX3311XD66adXRmS26DHGGGOKpRSihzF5avm1RArNYG3dNguGpZaHKc1cV155ZW63eWOMMcZ0PKUQPYCDcq0CA8HDdh0Jjszqnj5t2rSKT08jGN0YY4xpZEojevDV4bcTjM9T7b9bpCGemh3SIXqI60gQPPTeQvzgyKzBCS16jDHGmGIpjegRiBq6pmd7a6WB9R3lx5OFnlv49cBTTz0VxowZE+eNMcYYUyylEz2C302MGzeu8qNRAsvEFwWGXbx4cRQ9r7/+enRiltGNMcYYUyylFT2rAgyL4KGJa9asWaFv375hwIABlXXGGGOMKQ6LnjqD4Hn33Xfj/BNPPBFGjx4d540xxhhTLBY9dQTD8s8twW8ohg8f3rRkjDHGmCKx6Kkz9NrSiMz89NS/oTDGGGPqQ+lFT9pLCxFSJBh26dKlUfjMnTs3XHXVVRWfHmOMMcYUS2lFDwKHsXjooi40Pk9R4gd/nkWLFsVxeugldvbZZ4devXo1rTXGGGNMkZRW9DAWD6Mtp6IHWGYQw6KgaYtu64C40jg9jWB0Y4wxppEprehB3FDbkid6snEdiXx6qPWZNGlSpfeWRY8xxhhTLKUVPWuttVacpgKHmpciRQ+GZURmOTIjekaNGhXnEUHGGGOMKY7Sih7+q4UTswQO/9hSc1eRzVvU9BDmzZsXhg4dGgYOHNi0xhhjjDFFUlrRox+QInLw76Hmh3mET0f/ZFRgWA1M+Oabb8bfUDAqszHGGGOKp7SiR4wfP/5D/94qGoxLExc88sgjHpHZGGOMqROlFT2InDyIL7qmJ/Xp8eCExhhjTH0oreip5qyM4KG5qyhwWManB6ZPn15xZDbGGGNMsZRK9CBmFOTLkw15Y/d0FBiWWh6NyHz55ZeHyy67rLLOGGOMMcVRKtFDLQ5+O3JazgsInyJ9exA8+PQgevr16+ffUBhjjDF1olSiRzAej8bpqTfqsg6PPfaYfXqMMcaYOlFK0QOMxpwHvbmK+vcWhqWWRwam9xZj9UAjGN0YY4xpZEoreoBmLHVXTwM/HS0KHJmXL18e56npGTlyZJw3xhhjTLGUVvQwInOeTw8BZ+aiQPRQ27NkyZIoeAYPHhzjXdNjjDHGFEtpRQ/iRoKDmh01d1H7U63pK4/UWJpnqnn9U4spQfE4Mvfq1Sv0798/Lqf5GGOMMabjUVlbStEjaNKSAKp1nB6MRXMVgw4yz3TZsmUVsUMXdfnxEFjWryjuu+8++/QYY4wxdUJlbelED7U7CB1qdQgsI3j0p/XWohociZylS5fG3lmKw5jqrYX4QSApfvLkyZXfUFj0GGOMMcVSWtFDLy358MBpp51WWa7FkRkhUw1qdCR4MCqBZdX0IHqGDRsW540xxhhTLKUVPUANT9o9nZofmrpq8emhZufRRx+N255++unxr+n33ntvWLBgQVyPyJHYYUotD0Jp8eLFUXhdccUVMZ0xxhhjiqXUoqcatfj0vPTSS2HbbbcNX/rSl8Iee+wRtthii7DRRhuF7t27h4ULF8Y0EjoIH01ffvnlcO6550aRBI1gdGOMMaaRsejJUKtPDzU2999/f5gxY0aYPXt2mDJlSth3333DeuutF2666aaYRqKHgE8PogfuvPPOyjg9Fj3GGGNMsZRO9Dz44IMxVGvCopanFtFDb6wsw4cPD6uvvnq48MIL4zI+PAgepogebTNp0iQ3bxljjDF1ojSih55Z+oO6QvpjUdZrwEL8eloLQoZAU9acOXPCAw88EHbffffw6U9/OtYAgWp2MKwEEDAiM39aN8YYY0zxlEb0SNAgfKjNoYcWyzRnUetDPD8hpRaoFhA0iJ3jjjsu7LDDDuHzn/98+PrXvx6uvfba2KzFemp2mEfwMBIzzs8MTnjrrbf6h6PGGGNMnSiN6EHkIHxSED/dunWLYod5antqBWOxXY8ePcJhhx0Wdtlll7DpppuGAQMGRLHDeoIcmBE+d9xxR+jZs2f43e9+F/r169eUkzHGGGOKpDSih1qdrB+PxuqppTkrC0KGQE0OUJNz7LHHhnXXXTdcf/31MQ7BgwAiMK+0EyZM8Dg9xhhjTJ0olejJIy++Wto8EDxZ/vznP4ePfvSjsfYH6OGFUSWOJHrw6RkyZEicN8YYY0yxlEr0qOdWGrLxqv1pLW+88UbshcVghIgaapN+8YtfhI997GNh0KBBMQ0ih3Wq5aGJC6ZNm+Yu68YYY0ydKJXoqSW0FhyW6an185//PBx99NFhyy23DB//+MfDj3/84/Dqq69GYyJ4VMuD8MGRGSZOnOh/bxljjDF1olSih19FpLU6eYE0tYie1157LVxwwQXhoIMOik7Rp5xySmyyeuGFF6LIUc8tOTLj88Myvcbo8XXxxRc35WSMMcaYIimV6GkttaQVy5Yti81WCBoZEKGjgOBBAGmcHmp7aEobOnRoTGuMMcaYYimN6CkKhAyCRiB6EDYEDInAYRRmCR+tA2p71LxljDHGmGKx6GknGEuih/nUeFpOAwKIKdB7S47MxhhjjCkWlb8WPXUCgURTGDzxxBNhzJgxcd4YY4wxxWLRU0do+lLPraeffjqcfvrp4dJLL43LxhhjjCkWi54c2uLI3BowLP481PS8/fbb8b9b/K7CGGOMMcVTWtHDIIL8i4t/bqVBf2IvirR566mnngpXXnllnG8EoxtjjDGNTGlFDz8g1Y9G6yl6MK4cnydPnuwu68YYY0ydKK3oQdhkf0AqihQ9INEzY8aMMGrUqDhvjDHGmGIprehh9OR33nmnaak+YFgcmXFonjlzZujTp08MxhhjjCme0ooeankuuuiipqV/gRAq0pF50aJF0aeH31f07t27YnRjjDHGFEtpRQ/+PIibaqEoaNpidGaYPn16GDt2bJw3xhhjTLGUVvScdtppUdzU05EZw1LLIwMzIjPd1o0xxhhTPKUVPTRv4deTB+KnKPDn4VcU8Mgjj9iR2RhjjKkTpRU9AvHz4IMPxlAPx2b9eHTJkiWhX79+oW/fvk1rjDHGGFMkpRY9auJKQ55zc0eBYfWHdUZkHjhwYOjfv39cbgSjG2OMMY1MaUUP4gaRw6jM48ePjzU948aNiz49gwcPbkrV8bz33nuV5q1p06Z5cEJjjDGmTpRW9DAic564obmLdUWBT48GJ3z00Ucteowxxpg6UVrRQy1PNZpb114QPfr31oQJE6IjMwYn3hhjjDHFUeqanrzfUFD7U1RND4alaYuantmzZ8cmNvx6tM4YY4wxxVFa0YO4wX8HPx78efDroQt7kc7MGFa9t/gdxZAhQyqixxhjjDHFUlrRA3JmTgM9uooCw+LIrB5c+PRocMJGMLoxxhjTyJRa9ABj82icnrzmro6GWh6JH3x6xowZE+MteowxxphiKb3oyaPIsXrS3lv8hsK9t4wxxpj6UArRg78OIQVhkxc0YGERYFiJHgw+bNiwMGDAgKa1xhhjjCmSUoge/qhOSOH/Wll/njQUCcJn/vz54bLLLvNvKIwxxpg6UQrRg69O1l+HXlsIIfnzKFAjVKTowbhyZH7ggQf8l3VjjDGmTpRC9FQDkZNHtfj2Qg3PokWLouih6/qkSZPCyJEjm9YaY4wxpkhKLXrqDYZF7BCAf28xIrMxxhhjiqe0oid1XgZ+PEqzFk1ejz/+eIzraDAstTzU+PCXdXx6/Jd1Y4wxpj6UVvTg48MIzExpzkLwIHyK/A0FYkf/3XrjjTei4JIjs0WPMcYYUyylFT38goKBCQHxQw2Plot0ZFaXdZg+fXoYPXp0nDfGGGNMsZRW9EjkUNOjWh6g1kfzRZCKHgYn5P9bxhhjjCme0ooempZoxiIggBA/6saeHciwI0mbuJ566qlw5ZVXxvlGMLoxxhjTyJRW9AAOy9TsaAwf5hWKAkdmRM+8efPCVVddFQYNGhTjLXqMMcaYYim16MmD31BIBHU01PIsWbIkzlPLc/LJJ4fevXvHZWOMMcYUS2lFT9plPQ00bzEtCvx51LzFOD12ZDbGGGPqQ2lFD87L1QLCp7VooEFqcVLDaV7xBOaXL18ep4Ajs0dkNsYYY+qDyuZSip68ZixqedR1vTWouSoLYogaHQK1Owrvvfde5d9brukxxhhj6kdpRU81Z2WEUC1d1hEyjLczfPjw0KNHj9CrV69w2223hcWLF0eBw3oMmooehbvuuisMGzasKSdjjDHGFElpRU81qOWhFqi1zJo1K+yyyy7hK1/5Spxuttlm4TOf+Uw45ZRTYi0QxqQ5C8FD7Q9iiDhqeY499thw8cUXN+VkjDHGmCIprejZa6+9coPG7mktdD1nrJ0777wzzJ49O0ycODHm84lPfCLW+ABNXPLtoYZn6dKlcf6hhx6q+PQ0gtGNMcaYRqYUoodBB/ntRErquKxAGgRLLT8czTPWmDFjwmqrrRYuuOCCuIzzMrU8CB85M0P6l3WLHmOMMaZYSiF6qLlBzKQgcmpxWK4GxsIxOe3Fdfzxx4d11lknXH311XE9cfLvYV5MnTo1+gIZY4wxpnhKIXryBA5x1cgKpObI1t7QZLXxxhvHPF577bVoTAU5Nc+ZMyf6AvG7i6FDh8btGsHoxhhjTCOjsrZLi568JqtqoqdWR2Y5KAMi55vf/GbYaKONoqDBkNQCEWRU0k+YMCF2VT/rrLNiby+w6DHGGGOKpRSiB8HDgIOIHwWETbqsgF9PLaJHzVWvv/56+N73vhc23HDDSjd0BA7NWhI/iCNqhOjVtWjRonD//feHESNGxLQWPcYYY0yxlEL0ADU4gwcProibjhI98MQTT4Q99tgj+g7JMRkQRAgf1fbImVnQ08vj9BhjjDH1oTSiJ0s1YVNr8xaChyatT3/601HwLFiwII7FQ1f2hQsXRtEjfx+miB5qf2Dy5MkVR2bX9BhjjDHFUlrRU21EZmhuXRZqav7jP/4jfO5znwt77rln2GeffcJOO+0Utt9++9hlXYKHWh4EEMZVbQ9d1uneDhY9xhhjTLGUVvQ0Ry01PZMmTQonnHBCOOmkk8Jxxx0X50888cRw5JFHxkEL0+Yt5gnU9Lz00kvh7LPPDn379o35WPQYY4wxxVJa0aN/bLXXpwdjMcIyUJsj46XNWIzITDxxBNLRbZ3RmAcOHBjTGGOMMaZYSit6cDrO9uhqi+hRU1VqNGpzIBU6zBPUgwto3hoyZEicN8YYY0yxqKwupSMztT151CJ61GRF8xWGY6raHMQNUy1rPTU/8Oijj1Z6bzWC0Y0xxphGprSip1u3bh3yGwrV4kjUIICYJ+jXE8SrxkcCiHDvvfe6y7oxxhhTJ0oreqjlueiii5qW/kVbRmSW6EHQgESN4hQvwQMYHEfmPn36xOVGMLoxxhjTyJRW9ODPg7ipFooC4YNQohbotttus0+PMcYYUydKK3pOO+20KG7a68hcCxhWPj/MMzihx+kxxhhj6kNpRQ/NW/j15IH4KQIMSy0PAfGjH49qnTHGGGOKozSip5ZRlmtJWysYV+GBBx5w7y1jjDGmTqis7fKip5YmqyJ9ejAuzVtvvPFG/E2FjG6MMcaYYimV6GEEZnpsNRdIU6TokRMzwufPf/5zuOyyy5rWGGOMMaZISiV6aglFod5bwB/a+RWFMcYYY4qnVKKn2gjMKaQpSvRgWByY9U8uflY6YsSIOG+MMcaYYimN6KmlR1ZRvbcA42qAQn5DoS7rxhhjjCmW0oiezgCGpaYH3nrrrTgac79+/eKyMcYYY4rFoqfOUMuDT8/cuXPD5ZdfHgYOHNi0xhhjjDFFYtFTZxA98umheUuOzDg4G9OR8CAjsNWcyjJBI4Kn65kHrWOqezK9N0mvtELp06nilZ6pIE16THn584woH1AabcdUcWyjebbR/tJprfHkR9Cy8iZOy0ojiNc6tiMAcarhZX758uVxqu3TPCFdx7yWjTHtR8+aRU+d4OW1bNmy+ELEkXn48OExvhGMbjovKmRVQGqKONAQCZpy/2le67XMdto2jdM+9BsVCm4JD+JJq+0IrGM/yp8p6TTVPjWfrtc69pXmwTKB/SgNgTQ6Du2fuKVLl1biSddS/JIlSyrxOj/mZROWtW+m2h/bErQN6zlO1rPMutRu7Id4lpUXsKx9aj2BZYIxpv3oeSul6Mn+aX3w4MGt6uHVHniZ8dKDp556yo7MpkNQAcnDq3mgkKXABRXEBApb7kUVrqxjnu0VR7p0m2w65aO0kL482DfxpE/RPrKQVseaQnr2k4U8EBRZSJ+XD9Qar/NK0bln4RiJ13kTsA0ii3Xsg3mtUz5MSadliSfiJKaYN8a0H54zKJ3oGT9+/L+NycPvJ1hmXRHw4lq0aFF88b388suhZ8+eoVevXk1rjWk73FsUlCpECRIkBD3UKjw1ZZusoGCZwjYrTMhDhbEgjmXiubfffPPNGGbPnl3J45VXXolNuX/7299iIB37ePrpp8NVV10Vw9ixY8OcOXNing8//HA488wzw/nnnx+d/dme/Tz22GPh3HPPjfF8rPz973+P50veF198cRzhnHXPPvtsjGccLJb/+Mc/xvTsLy9+xowZMX769OkxnnzIj2WOn/yUniEmXnjhhXjOjKrOsbLMOafiJoVjJ7CO/QjykO1kW9azPUKHjyNtm25njGk7PE9QOtGzySab5I6+zDJ/Wi8CDEtBwIvu7bffjv/donZJ64xpK9w/KjSzECdhQzruP9UeEE/hSgE+a9asKAwWLlwY17300kvh7rvvDnfddVf0PSMN8M+4s88+O5x66qmhf//+4Z133onxN954Y9hnn33CjjvuGH7wgx/EvGDo0KFh2223DTvvvHP44Q9/GJ555pkYjwA66aSTwmmnnRZOP/30Sv533HFHOOKII8Kvf/3rcOyxx8YPBLjnnnvCMcccE4477rgoil599dV4PoghRErv3r3DeeedV6mtnTJlSrjkkkvCpZdeGj8wEEkwderUSjzpn3/++Rj/+OOPV+Ilnsh/2rRp4eijjw5HHnlkOP7446NIIh7b7LnnnvGc99577/gDYUAscT6///3v47lhB9LPnDkzPPfcc3E6b968D12DFK6XhBCBZabGmPajZ6l0ogdxw8s6T/Rk4zqStADiZTpq1Kg4b0xHQCFKjQMCggIWvzEKWOIfeeSRWFuBkDjllFPisAnA71AQJIiVfffdtyJKbrvttvCrX/0q/PznP4/bqMblvvvuCz169Ig9D2+44YaYP/Hsi7hrrrkmTJ48OdbocL8j8F977bVY+4NQkU8LhT6BDwGCakL0jDCVKFA82zIF8liwYEFMk8J6NSOl1BpP/orn/KiB4Zx0zBwLNTyIQwQfU9JyrjRbI3xOPvnkGA/YDXG06667RkGHOCI9ogvfPvJA2FHjxX7ZH/swxnQcpRU91PRAKnDU5LXWWms1xXQsGJYXpqBaXo7MnRHdCExVsPCSTgsH1mk5vXE0z3ZpfArx2XRM9ZUrmGcfxGcLOCCO9cpP+ShtmpfSgtJpG/KnMNO81guWhdalacg3jVP6vO1SiKNgz8aDjlXrKHQ5NuIRLX/961/DkCFDYg0FooT4cePGxdoHwi9/+cuKiCEtNSXUZCB0Fi9eHONZT4GMUKHWJL1HUzjO9FxS8o4dONYspOU4lZemOi+ds0gFUArxbMMUWE9eiAXitW9tV2u8ronOO7ufPEjT3Dr8+O6///5w8803x2ErgBomaq++973vhe9///uVGjJE0IEHHhhOPPHE+J5QjRpCLxVD7E/HnJJ3HNm0zKf2xgaK0/aaZ5rGG9OI6P4tneihLZ/CQaIHfx7EDstUSRcFLxS9PJ988slO+xsKFQIcb/oSJE4vPwoLzoU43TRMlZ6gedIgKNI8Savt0vTah2oCtE06Zb/KV9uSl+I4Nu2HwLLWK055MOXLWvtL12kbgiCN8mE9aXUexOmY8mB9is6P9DQrPfTQQ+H222+PTScUiqxDiFBD89vf/jb86Ec/qjSj0Ezzm9/8JvzkJz+JzS40x5AfU2oMEDEUqAgl9kuodlxm1cB9o8D1f/3116MYZZnrSNMggojrTw0Q148mRWrkDj/88HD11VfHe5f7BPFK056EMSGL7gGC0jDPPcw8UwLPKvE8N3p20vXGNCrcy1A60QOIG0ROGooUPBiWLzRePFSLX3HFFZ32L+u88DheFZbAVC89Ai9B0qRigaAbSC9XiSMta550rOMFq5erXqzaTqKAfJmm82zHetJq32xLvumxKz3pQOvIH5RG8Xnkxev4gfw5Fo5JeVGI0XSBoL7zzjtjswfx+M4wEjdNTD/96U9jsxDgO4OPyI9//OPob0ZNIOnJg+YSanRw+uVhZT+E+fPnV+wnm2UhnjTkRUhtYVYd3Cdch+y1YJlrJFjmuhLH/Y244YNt0KBB8b4iDqHEu4umM/yp+Jgif+IRTzSl07zIPap7QLCcHgsiSsvsV/kzBd8/ppHhfodSih6gyphCiVB0d3W9hHip4Ntw4YUXxqaGzgjHyo3Ay4154KWXvnwJulnSF2cWpc+7sVinF3EK+bCN9i2yy4L0eXlIhED2WAnsmy9orr3icDTlfsChliAHW3xk6GVEYcMXOA62HCPxJ5xwQjj44INjcxJNRXDrrbfGL/Ldd989riMv8mc7fGJwlu3bt2/0+eA4eAhxklWzB+SJGOA+Ii/2rwKMKXE6P7ZlXus1zzZm1cK1SJ8tpro2rCNwT+h6so7rmXc/kA9puW819tdNN90Ut+Fewol7q622CjvssEO8b4F3EPc4tYX4XGn/7Evo+Mhbz6KeJ9YZ04joHi+t6BESPzQHFAkvDwosoOsshSh0NqNzPLzc8tBLNk1DlboEETUc6g1EdT21EWxDLRfLrOOG48VLPC9S4vkSxU+FZcWTlpcyNWOKx37EUwOC4MDHAbuyP/xW+L0HNWjkx/HhR0FPmsMOOyzWotx7773x2LneP/vZz2KTEU1EXA9ArHz3u9+NtS448eKDATie0ixKzyWGGqCrMvlwbNTCsF+uJ1/iiqcHEYIKZ1+OX4KD+RTFgwofzpV5YD3LnI/WEYjH7sQzVTzLbMtU86RlW6bEmVUH14FrwBTSa5Rea11P3QeKY5kp9xF5KJ8U0hDPc4C4oVaIGh/iEPo0m33nO9+J9/qVV14Z43nW8G3kmeF54rnmeLKwb2MaET0rpRM9VAXzN3WaEYBu6mriouq4KHhZqNCZOHFiGD16dIzvjEbXSxmRQUHOmCQ0uSAQicfhki6/1FogKOiCDHxt4jD7i1/8InY9posz4Jvyu9/9LhxyyCFxqmYd7NCtW7foxHnAAQdEUaJ4BAkOuYgS9g/shzy+9a1vxfSqWeGFzoscocJ1pVofIcCxc4xnnHFGrPanpoXj56XOCx4fGfxfECZcGwoSCgXEG4E8SI89VOhoSsi7dqyvRjYPCicVXmm+zCuONCrEVCiyzDqWFZfGKy9NCUpHnFl1cB25Drp30uvF/cYHga6V7gEC86wnKI5A2rRmSNso/xTV3LAPPja4//l4IC3d+nl+6M3HM0cPPkDg0zMPXzOEPNsb04jomSid6KFGh692kEMzY+YQX1TvLUgLHAppOTLnGZ04CjDNq/AVeqmRpwpNYJlQjfTFyIWngAdegNRWMOYJIoGaDUBsfPvb3w677LJLrBnhuIGaEbrkInyoUtc4KIgHXow4aiM41FxDPNsQ+JJEUABfotSu3HLLLdGJl+MAan1YJp6vVNIBootjIx/isrUmKaldUvLiQIVMFtkrRddR1wjy0mXjNM9U94PyEqxLr5PiCBQ4ihNap7y0rDjdD+l60znQdQLdD6B4hWy8lnVNRRpPuhSlzcaDtuMjh9pJxBAfBsTzPPMhwTuAjxA+SIAaJJp7r7/++vgRJGEO2X3kHQtIwOXBNtgkzy6puFcgTs8H22if6btT25Ne+WbTk4+WlXee0FMeeWi7LNoX4pMelzRva3/4/SEsee9Rw0wa4N1KPB9pBL3zeFcSTw03zefUqgMilfcv15H8OX/gnYvAZT1T5cN2xJFW70zZUudIHjpX4lifkneu6TYp5C9bp8jeeeSlB/JPr42Ot1p6xZdO9KTChloedWGHIrusc6NwUXixXHfddVFkVCNNz1QhhZsqjdPNyY1LcxI3MjUsCAeEBtD2T00LY4bg9Mg6QKAwABu1KDThUCNCfogMakJoTuLh40HUw1jtBjXGdA14xnmn8D7hnYAA0ocSBS5jOTH4JLW7FNpAbS1d7fl44mOSWiXyoZBGHFHYU+iQp95hNKWRjncL7748kUFcXjxN3Nl3I5B33juKPPIKOtJq/ynEkT/Hx3ESEArkzzsScchHGLXQDAfBOvLADvhUYSM+ECVKGJiWpkVaG/iQVE9N0jN0ATVt1HIjQjgmhi9AdFKjTo01H3vsl9pyarsRo/vvv38UMsDH9G677Rbf8fvtt1985wPp8TNk34hXPmg5To6ZZdZRw8d1Ip7epBwHeVMTTxkAiDIG7KQzBsNl4G5Aeq4tNe/4JiKIOS/isRvznD/XHPtzXrrulIfEs4xNWc8ydmcd8Wl61hGwgYLuH/ZHqIbWlU70IHKo1cGvg1oe1frwgGq+o+GicaEwMA89NwyjyEKe0Ynj4nNB9dLgxuEB4+blgWA9NSj4kjBKLd2acWIERM72228fhQ0P1l/+8pcYzw1K7yF6AnH+PEDsi/y1H9188pdJ4XjSFwPpjTFdD5513gUqWATzvBf4uCJQmPFuUhpqifhlCAF/Ogpd3hfUIjMI5k477RS73PO+AXonMiYRBTjDL1DQkZ5Cl5ok1tM9X7W91DTR+5V1DIZJDQbHQS00aal55n1HQcjx87GG3xK+d8STFjhO0uLgTW0VBSHvPZrGEQ4DBgyI+fO+A/KgUwIChtHEJQKuvfbaim8gw0jw3gQ+KPmtCcKHX6pw/BwPgoD98R5n0FDswD44XgLngw2IUyANxy2BJNtTppBe58o1YP8cG3bCJtqWsoIaIOIQaXzQch0RqxwTH8gMOMr1JJ4ONxwn54ed8FMExBJlCOeFHSiLuF6INjpz4DtJz1SJMFwcKJu45lxntQoQz0c2abGd0iOciCMteXE9gP2SnvKMeMQVx8l5HnTQQbEiAbBDNVRulU70UEWocXmo6eHio6RTAVQUEhHcYBqRuZrR9WJhPeobdc1XAL0x5ATNjYja7t69e5zyJcaNz8OBDw7NRHyZkQ83gx7gFD1E6YuNfRMQNQTm2VY3FMdEqPY1ZYxpbHi+ee555vUOYMp7gucemNf7i/dD9l1AoUxa0vDBRcGF8KD5RvlSQ4IgwW8IdwO9Z5hHNCEyzjnnnCieOAYKZka8pnaJ5nV9rCGEqJWg1oJ3pWpcaB7HV4lalFSU8HsVxArxiBmagzhWxBYfkXyYnnXWWZWmeN7ZiC81xeP4LUEh4Udajp+4LLKh7CVITz4pxKVp2Va2xeayna4DywpKJ1jmOpBnCtuSPg9dsxTyycaB7gumiDXKHNXQEIdd8Q/juiMksRv5IMy4ZrR4cP0p48gHYUYFBGNSEc+HPulpuUjTcz9gC1opiJfrBfvNO05QfOlEz6qAi8kDoRsBdSqfnmpw4+mm5qFiLBdeGtwU6mqadyOmD0sKadk/NwqBZR5O9sE2CnqoCDwoaXpN2Ub7boSbxhhTGzzXejcAz7ueeT3/vA+oZWCqgpppWvBQ4BKyKF0W4siH/IXyYz9pXiyzjkBBq1oP3o/puwqhwzrVbrCO9Aqk17lqP0CcQh6cA/tgCkqrfRCY10elbMfxMmU74iWemFcenAdT4mRrtld+TMmHeabkofy0Ddsz1fZ63xN0jOSpNFqn4yOwPj1PxZOXltN9AFPyYH0e7DtLun2WvHgdb4qOoxqcC5RW9KBAaeIh8DAUDReOGwUQPXxpVEM3GtNqNw/x3Dy6aLr5dTNrXtvrhtB6AtsSRxrFEZSemyr9WiNoO23L1BjTteA5572gZ5359D2hZ1/vlPQ9o3SsZx3xeu8Qx7LSKL3iSKf3DeuAKXGsV57pvNKl27CeoH2qgNQ+heaJTwPxbMc82+o8iFdcel7al+aVjkA6psSxjmU+ZJlnH4T0WLWdllmXF8iP4yCQVnZByBGnNKxjmbxYZkp5QTzLbEcACSO21XbKm3VMVbum89c827Cs/bAtU7ZnHbCeeeXPlPyIZzndlnjtX4H0OkampCVOx0GoBnlDKUVP3ojMtTZt6QIxBeYxfp4RlY4pF5KmLdqkta4arFNIYZmLy1T5ZtH6dF16Q2ieqeaVXnEExSmfvDhjTNek2nOevjN47wHT7LtDhRwoH23LuyvNh/n0fap8lIYp8QrZ9UB8+h5m/0JptS2k6YnTsabpdF5AHEH5Ko3SZ1Gc1uv8IN2G+PTc07RKo3gFHZOmige2TfPXOi0DadL1wDbaL/OcZ5omTaf9Ctal1zpNqzxB69I4HW8W2T4vPWhdGqqhdaUTPYgbRA5+PPj3UNND+zH+PbQlthaMrsCFITBfzYhcHNQpbZGMxtxIRjfGGGMamdKKHnpv5YkbmrvS7ustIfVKkOqnii9PrQLptA7P9c48OKExxhjTlSit6KGWpxrNrcsi0QPU4OD7oqq9PDCuxBHdFSV6jDHGGFMspRU91OZQq5OF2p9aanrU1oiPTmvAuBJJiB7GPjDGGGNM8ZRW9CBu8N/Bjwd/Hvx6+P9Trc7M1O6ouYoxGhiHgEGe8sCwpFV60rXUZd0YY4wxHUNpRQ/ImTkN9OiqBfnzMKgSI0iut956cTArCZsUDItIYsqgTIxkyd/AjTHGGFM8pRY9wNg8Gqcnr7mrJTAWo3d+85vfDBtuuGHYYIMNwqmnnporegB/HgbIojmMn8S5ecsYY4ypD6UXPSk0dbVlgEL+ncK/QHr16hW+9rWvxRqcaiCG5MjMkNkanLARjG6MMcY0MqUVPfxslH9vpX9Ux69HPyJtLYgYmqyoveG/IJtttln8u3A10hog9qN/bxljjDGmWEorenBiRuBQu5OCCOJ3/62F3luIHpg+fXrYZpttwgknnFDpoZWCYRkym5+x8TfZG2+8saaBEI0xxhjTdkorenBazmvKkkNza0lFD0Lmy1/+cqzpqebTA3RVp4bnjDPOiH+cNcYYY0zxlFb05I3TgzMzgidt8moJjdMD/N7+S1/6Ujj55JOrGpF4BjBk1Gb2Z0dmY4wxpj6UVvTQXZ0mLoQPNT40cyF2au22nv6IDdHzla98JfzhD3/IrekhnWqFYMqUKR6nxxhjjKkTpRU9kPeXdQYorKUHl3piAaIHR+bf//73VZu3iKeWB+i9ZUdmY4wxpj6UWvQANT0ap6eWXlsCY0ngMMIyPj3HHXdcriOzUO3Q3/72N3dZN8YYY+pE6UVPFnpu1SJ+EDf6wejMmTNDv379wh133FHViPIBmjVrVrj44osrRjfGGGNMsZRW9CBu8gJNXEcddVRTqpZBxBBoskr9e/JgHWlIO3/+/DB27NjQv3//prXGGGOMKZLSih7EDY7MWdFDry6mtUKNj5q5mjMgadT0RXOYe28ZY4wx9aHUoifPYZnBAtvi29NaUkdm9jN69Og43whGN8YYYxqZ0oqeaiCE2lLT01poCuNno9T23H///ZUu6xY9xhhjTLFY9GSg9oVaoCKgloeBCTEw3dWPPfbY6MxsjDHGmOIprehB2FQLRdX0YFhqenBmpqbnvvvus0+PMcYYUydKLXqyjswMVshIzbUMTlgLGJYRmTWgIbU98ukxxhhjTLGUVvQU6bdTDYkeGfjRRx8Nw4YNi/PGGGOMKZbSip7moLanKGjW0v+3nnjiCf97yxhjjKkTpRA9iJjWBv2PqwhwZF6wYEGcPvfcc6F79+7hkksuaVprjDHGmCIpheihKSt1VG5NKAIMyxg9ixYtCosXLw433nhjHBfIGGOMMcVTCtEzbty4sNZaa1V+LNpcGD9+fGGiB+i9tWzZsjj/2GOPxV9RQCMY3RhjjGlkSiF6AEHTWmpJWwsYFp8eAvOTJk3yX9aNMcaYOlEa0ZPHqujBhT8PAZ588skwatSoOG/RY4wxxhRLqUUPzVg0faXNW0XV8gBih19QwKxZs8L5558f+vTpE5eNMcYYUyylET1yZsa3hx5aIKflbCiyeUujMc+ZMycMGjQoDBgwoLLOGGOMMcVRGtHz4osvRsGT/kEdgZOt6UEQdevWrSlFxyLRgzMzMCKzmreMMcYYUyylET1HHXVU7JmVgujJInFUBDRv0V2dwQkRPhMnTvTghMYYY0ydKI3oqUXI5ImhjoSxegDR439vGWOMMfWhNKKntUKGn40WJXowLGP0UMsze/bscNlll1V8eowxxhhTLKURPZtsssmH/HmqgY8PaYtAvbeY0ox24YUXhr59+zatNcYYY0yRlEb04NPTkoMytTw0g5G2KKjl4f9bMGPGjHDllVfGeWOMMcYUS2lEjxyUET7MZ1END01bees7AgyL6NFf1hmRefjw4XG+EYxujDHGNDKlET1Al3SED8Jm6623jmP3EBRHQPwUBYbFp4du6zBlypSK6DHGGGNMsZRK9AC1ONT2SOQoUMtT1KCEAsMyMCE+PUuWLAk333xzHKDQGGOMMcVTOtEj8N/RgIStcXDuKBA8GPiFF14If/jDHyq/oWgEoxtjjDGNTGlFz6oCnx79f+uxxx4L1157bZy36DHGGGOKxaKnjmBYmrdSR2aPyGyMMcbUB4ueOoJhcWKWIzOiZ9iwYXHeGGOMMcVi0VNnJHzw7bnhhhsseowxxpg6YdFTRzCsem/xG4pzzz039O/fv2mtMcYYY4rEoqfOIHhwZsbI/HB05MiRTWuMMcYYUyQWPXWGpi1qe2DChAlh1KhRcb4RjG6MMcY0MhY9dSbtvcWIzGPHjo3zxhhjjCkWi546gmHVc4ufjvKzUY/IbIwxxtQHi546gmFVyzNz5sw4GrNGZDbGGGNMsVj0dAAYDAdloPlKPjtpPPNaVsCRefTo0XG9McYYY4pFAseip40gXuiNJQdlfiSqecLy5csraVjGuMwDPj1yZDbGGGNMsVj0tBOaqxA1KRiQOEQOU9JoQELWya+Hf29Z9BhjjDH1waKnnajW5tlnn42OyZdddlm47777Yo0PhtR6phJHTJctWxb+/Oc/25HZGGOMqRMWPR0AIucb3/hGWH/99cNnP/vZsN5664Vzzjkn/k0dY1LjA2kTFyMy9+7dOwZjjDHGFI9FTzuh6/mee+4ZPvnJT4a//OUvscbngAMOCOuuu2648847Yxr59dCspaYtBNDdd9/tv6wbY4wxdcKip53wp/QNNtgg/Pa3v22KCeGRRx6JoueEE06o1OwwVY2Puq1PmzbNv6Ewxhhj6oRFTzu5+uqrwxprrFERLxhv/vz54Qtf+ELYd999w9y5c2M8UNsjvx7AkfmKK65oWjLGGGNMkVj0tBP+lP6xj30s3HvvvXEZ4y1atCjsscceYe+9946DECoewUMtz5w5c2L8+PHjw5AhQ+J6Y4wxxhSLRU87OeOMM8Jqq60WHn744aaYEHtu/eAHPwh77bVXeOWVV5pi/9Vr6/bbbw8XX3xxOP7440OvXr2a1hpjjDGmSCx62smwYcOi6LnlllviMsZD2GyzzTbRwfmNN96I8YBPD07NAp+ecePGxflGMLoxxhjTyFj0tBO6q6+++urhggsuaIoJ4e9//3vszXXIIYdEAQQYVT24ZGCcoBFNxhhjjKkf77zzjkVPW0AtbrXVVmGHHXYIr732WqzNOeuss8Laa6/9ISdlBI96csnA/HurX79+0QeIru84QDcXFi9eHMf+mTdvXu761oSFCxfGKfujGS67vqXAdun+WSZPjo2pzkPxSldLIC9swjz5KM9aA3mkx9SW40mvjbbXsbUlkAf2w/bpsdUStA1T2arWe4Jt2UZ54XBPXgTiFNp6r7Ft3j2RTddSUD7p/ZBN05qg7TkeXYO2XEftn+1Te7XFTmynkJ5jLYHrpnPR9jq2bNq2BGyVl5fsUEvg+GQvlnXu2XTNBd1POkfOvy12I5AXU/IjD9kxm661gWPhuW5PHgo6L1oG8tbXGtL7nil5c97sJy99taDtOU9dO6aarzWwnfIi77bko+0I+MzmpckGzp/hZS666KIPlcmdmU4jemDw4MFhww03DDvttFP45S9/GQcn7NatW3j99dfjegkeiR6W4eWXX45/WWckZ3p/8UuKbBgzZkxlntGee/ToEdOnaVoTGA+IfZAf27Nf/Iqq7bda4AepbMOUMHbs2Hj+f/zjH+O81ivfWvLn2C6//PI4sOO1114b8yI+za+1gbwGDBgQevbsGWvTyCu1ZS2B7RCw1OZhR+JqPR6dy1VXXRXPEWGMvWo9JvZPXkyvueaaMHDgwHiO5JuXvlogD4Xhw4fHY+H+4iWQ2pv9cIxtsf+ZZ54Z89f9rXswL321wLY4+5MXeRLIs5Z8SKvt+vbtGy688MLY65K8dW/kbVctkB+Be+L8888PQ4cOzU3XXEjvIz3P3BNtORauXTrfv3//eFyKb2vAZtwTvCeYT/dDyKZvLnBejD7Pvapt02NvTSC9riPPEHmxjItALdeA7XXdec/wtc85skx+edtUCxyTnkm2xfY8Q7XannwI5MPzSBzTs88+O8Zn09cSOC7eE+edd1681/QcypZ521QLpCcvzlFxOu40XUtB9uKeoOzQObfF/gTszT2h90Q1m7Ffnbv2adFTIxgL5ctLFMGDAzOF9gsvvBDX05yF2EHoyLj6FxdTqthmzZoVA/4/eQHxxPTWW2+NNwi1S9k0rQ3URjEa9E033RRrmehFlpeuWmB7pmxHIK/7778/iiictgnEc8xK29pAXo8++mjo3r17nCeuJdtUCzouHlCaG4lrS14IU6YTJkyItufrgHPMpmtNkL1mzJgR/vCHP4RXX301N11zQeeAfbkPGBCzLfeE7KDryPa33XZbLMg5Lu0ju11rA9f+pJNOCs8991w857bcDwS2/dvf/hY7DCifthyXzpdfv1xyySXhzTffjPlw7tm0zQW2UV6TJ0+O9z33RDZda4JszHnh33fKKafkpmsu6FheeumleF+SF4Oi8g5iPpu+lsD23BO8J3TP6/xrtRvhoYceiqJTebUlDwL7Z7gP3hPctyzXem9xHmzDfcAHA8JH91de+uYC+bAdx4KI4iOw1nx0LzAvuzz11FPh1FNPbdMxpYHzYiBcBBTHyPPN/dLW55GOOJdeemnMgzidfzZtS4G8aO2gM4/e0W29J8iLe+Lkk0+Oy3ou8oKOl0DtEGUxtU2dnU4jeuSzAwib1HgSOMA6CR1gnqaq1iAV+sQTT0SF2hE8//zzcRDFjoAbLO291h4QgTfccEPTUvvgHBGjqllrDwwzcMcdd1SuX3vgul9//fVNS+2DlwXH1RHwkuWlrfutvVx33XXxPm8vFEw333xz01L7QHBqpPT28vbbb8evxo54YVLdjr06Al7qfCB1BAiUjnpPUKDxPPIR2F5ooqCmsyN4/PHHoyhoD3pmEMD4anYEfEwjqjsCbM8QKR0B9xcfIh3xnqBpiuFeOuIdzfOI4GyJ7HFThnfE/oum04ge/VCUwlDzGDU1IvMKFAKaKmgd22WD1gFflvITykvbXEjz4aVDW7EK8Lz0zYU0H5Y5B/LTMnZQUFxrAnBMtNWzD7Znmpe2pQBPP/10/IqTuORY2pIf2xB4ODg+xWXTtTZwHDrHtuSjcyFgI+WVl7ZaALaRjYGXNQUJcUD+kLd9S4E8EQNMZXeFvPTVgrZPz7Etx6RtOSa95FiuNS+OhSnwxUwVOS9uyKZtKQD5yT4IHx1XLUHba5lnMe1A0dYA3Au659NQ63ECtd80L3BsxJFHrfkoPefYnmdIgW15f8n2bckrtT955dmrNUF56Dj4AKQWV/dcWwNwHbn307zamq/e9zrOvDStDRyD3hOQl6Y1Aai5oRYX8tIoAOeATTgP4ph2djqN6OGiYTxNCRhUNwQQp3mmpCXo5slelDRoO+CrSwq71qDjISACOCbFZ9M2F0jPcTPPObAMLCtf1uscCen2LQUJMeyiG1PHWksAVYNL9JBPrccDHIeOSy+OWu3GNjoXnQ95tuXc2I78sJGORdektYFt2JbttC2F0pNPPlnJU2mUPt2+paAXP1Ndy5bu9bzAdrKR5nV82bTNBdKzPQUu23NP5KVrKcgehLfeeis2e1L4QpqupQAcD/nJPiC7tTbovGQP7NOW42kucIwcF/tRXK32B9mLvIBjbct15Hj0HHId02tSa5DtdZ/mpWkucA5p0DVty3XUlHyAphdqcWu1UV4Ajkn3PeiYs2mbC5wbdgLya0seCuRFAOXTnmtJTQ9Nb8xXs5nuH9mZc1BcZ6fTiB4ZDzCcbggMnF5AyF5QltmWPPJQGqUnXTZO6arlIdhG2zPVcq1k9wvkRQCtJ2h/tZBuD3oY2gLbcT10rm09HtC2BPJraz7AvL7Ea4Vt816obUEvLbbXNUzPk3ndn23ZR1pIkrfEZ62wrZ4rUevxpMdBSOPySG2RLhM0D6ngAOVZLd+UjriO6bbZ4+gIlC+0Nn/WpdulpHZVmjR/XZtqpNvp3tVyLWg7yOZVCzpm3et6plqC7bQ/tmdKnOKzdgJNiW8L6fbKV3G1wPml7wXNtwW2S+3V0vGkxy27yVZcA0iPjanmtSzS9Kzr7HQa0VMkuqDABdJFSi8iMGVdekHLjmyXBtvnX/Cgyy7ZlwRxoLgy2k52Qahx7rKRbCH7QbqegM0IFIBZsdbVkY3Se0m2ZBm0Lr230vSkJXRFOMf0fJny7pad0vVKz3rsQRxTpSsbnDvPlGwku2hZNpOtFM8yaRu9jCyF6IH0YeBCMs9U87qIushmJbKbXhJM9TCYfxVOuq9AL1/ZjHUKZbMb56/A+fOyxT7yR8FGxLFecczrpaw0xJUNzj8tkGRDBS2D7Cc7yY5d9X7jvDh3nafsILtAuo6AHXUvaYp9ywQ2Se8pPkZYJl7r+MBgneynZzG1H4H1jUhpRI8umi644tKL2agXsUhkI16oPAzYj2XbaiXYQk1/3EP4SDBNXxZ6eTBfNjhnvSAJLGMfbCM7cU8pSPik22r7MsH5Yh89b7IP8bqXmNcyaZknje5HreuqcG46vzw7MK97TFPiuccg3b4sYBuJGtkHED/YJXtfKR3bSFRrfaNSGtHDRSNUg4vbFS5oR4MteFGk6MEwK+0D3DsU5HlI/CiUCc5XL9ZsAcM62U1pshCvQqpMcF9x3tl7Ss8itqvm26X7jDyYdkX03HF+1Z47ofe6mljLDHbIPofps5eWk7Jb9tmU+GlUSlXTA4yzwEB0jKPCQGbpBSUNQQ+U+ZeDKWNKMM7IM888U/kiMCtJ7yG69zM+EoP3MW4G3WUhvjze/5c/RlngvCmUeEnq3F988cXYG5BeNbxg9SIm/oEHHoijwmI/xjvS/VfGZ1K24Z6aOnVq7A4uO6rQwT5TpkyJ7zPGHuMfhnT9J01LYqCRwS66L5gy3hB24IfVDK9x019uiveT0DOKDe+6+65oL8aZYrsygb2wBc8e49VhA0aWpncbAy4C9xaBtNyDpKfcpMfg9OnTo824t1jfiJRG9ADdiHfffffwsY99LHzuc58Ln/3sZ+NIw/qS5OJyIRv1YrYHvUw5d01lB7owMkL2f/7nf4a99947/mfGrOSDD1a+IGjW6te3X9h8s83CeuuuGz6/6efD+uutH3560EHhhb+vHFV82dLy1VgAX9i6n3jBfuUrXwlf/vKXYyEl6B7+ne98J3z84x+P6z7xiU/E55MRfinYdS+WCd5HDBL3qU99Knzzm9+MBQ+oIOK5PP3006OdCP/7v/8bNt5443DjjTfGdDzHXRXOLb0vGKR00003DZ/5zGfCF7/whbDmGmuEXXfZNY4m/8GK5xObvfXmW+H4444LG26wQfjfjf83/M9//0848ogj4ujCQF7YVYKyK4Mw5JdP2OsLK+y1zjrrhF133TWKZsBe2BcoH3/1q1+F//7v/w6bb755HO0fGvWZLI3o4evne9/7XvyfF/+Y4cLtueee8SWhkWWlXvV1WSZ42LnROW9ucuzAPC8A/pX1xS9+MRZE++yzTxzZ16zknx+sfPDvuvOusMEKkbPP3t8L9997X5i+QmD3OPuc8NEVL9bjjjl2ZUH1Xvn8xvQhwfPH8P28aNdff/2w9dZbx5oc4B7jC5wB5Ciw+Thh1Nv9998/vowZM6Rs8IzxO42NNtoo2muHHXaIgziCnk1+O/A///M/4eijj46/IaDmmpoOfvlCGuyqgqurIRtwftxj+un0oxMmhCemPR6uGHR52HD9DcL3vrt3mP3G7LjNn3pfGlb7fx8L3U8+Jdrq9FNPC2ustnr8vxqQFwG7deXnlHNDDPKPLcpBBlNlMEKeNT5uVTuNXYGBMCknEZXbbrttHNwXGtVGpRE9NM2ssUL9H3XUUZWLRTMEX5a8NEDxXf2mr4a+chB/uuH53QBfkfzj6tvf/nb47ne/65qehPf/sfKrcNjQYVHg8GIVf3/u+bDm6muEE447Pry7bIXoefe98O7yrtvkkIc+Hvj9yC9+8Ytw7LHHxq9GanO4twTpss0xjNKMSNLo6WUC0XPIIYfEf0b95Cc/iTU9iBnsxLuJ2omvfvWr4fvf/34U1Ck8w3qHddX3GOclWxCyNoADf9ItbPzpz4QZ058Kc9+ZE3bdeZfwta98Nbz2ykrxuHD+grDlV78WbcsoxLJVV7UZcG56z6dgP2rxt9xyy/ifP4Fbw1ZbbRUOPfTQWE5us8028d9vjUxpRA9q9aMf/Wj8Zw0XHUWPoqVqj4utIfBZ15Vv+mpw3rxE9EAQ+PqmoPr85z8fXwo/+tGPwo477hgLMLOS5SvEDDy+4utyi82/HHbYbvtw7z33rohfFs48/Yyw3jrrhquvGhfTRMp3a1UKJEb2phmLn3huscUWFdHD84bg4f7TlzvQtLXuuut22H/yGg0KHD4wEIoUNjRv8VxiJwqetdZaK77PKKT4gMNHA/uB0smWXRHuG72rOG/dRzyT8+fOC9/Zc6+w1de2DK++/Ep4ZUVYZ621wxG//s3KGtcPVoil9z8Ihx96WCwD9J8vvfvJs6vCPaEaLZ0n/jxf//rXw3bbbfehGkXuPWobqd2hphYBxD/WtL4RKY3oOffcc6Mvj6rKuegU6l/72tdiM5ec3tJajjKhAoepHgSE4uqrrx6r0QGfi1122aV0zn/Nwou2qVC/8fobwhc2/Xz8utxj92+H//3MxqHnueeFBSvstXz5u2EJvzUomejhfkL0qKcR9xZ/jd9ss81iEwPonuMlKoHEDyd5ASOO+At12dAziN1+/etfx8JGhRHg60OT87777htrKii4qfnp0aNHxUeFPLBtV4R7hfc056eQvrsHDRwU1lpjzXDSib+P62jyoinrj+dfEGtnEUaE83v2DGuvvXbFxYH7j3xk/64I5ybRo+eyf//+sSXkrLPOiucP+Pd8+tOfjs2swBSfHhyaG5nSiB5U6pprrln5kzYPDRcc0bPTTjtVnAR5aBpVwbYHzpmHQA87/yfjZYofFOIQqBHDEVwFk1n5AuHLkRfFwP4Dwmc+9emw/bbbhV122jl8YoMNw49/+KPo34PYoWmrqxZC1eC+4pzxE+NFy/NFkw1iJvXpUSEG1G789Kc/jR8pOFxC2Z5JzpeAgzxNC/j06B0FFFIUSPjZ9e7dOxbae+21V6z9GTBgQEyjDhpdEd1XBO4fzcP9f7s/fOHzXwjf2Hqb8MyMp2PctClTowi6tFfvlffaimeWjgUXXXRhvM9uuummmI7nWI73XRXdW3rX33PPPWGTTTYJu+22W/zYAFpBqAxASMuHE9GD+NZz26iURvRceuml8ea++eabm2JWvhR4+XKx06+jMgofzlvqH1GDDw/2ooaM7sVUpyMOEULUls2ePbvy0OiFUzabgQrqm2/6S6zh+flPfxbe+r83w7wVBXffP/UJn/rkRuGnBx4Ulq4ovMpIWigB8927d48+PTTHAOu494AeSYcddlhs1sKxWbWPZYTzpvChiVl+J4ANcdpF4PTs2TPGAV/g9ErFz0d0Zdtxbiq89e6ha//Xtvxa2GLzzcMD990f42DqY1Oi6Dn1lO7Rt+79FaKH7U497bSwwQYbxOElQLUcZbnn7rrrrlhjyPOI7QBb0quZWv7jjjsuNm1RBvzsZz+L6YYNGxZ/etuolEb03HbbbdGnp0+fPvFmh+effz6+JPiqlLpnHTd+2V60nK8eeHx2unXrFh2Yac6idoeXLg8HcfgX8LDIRhT8ZbNXCv4BZ595VuwZcs9ddzfFriic/vF+2H3X3cI2X986zJq5ssAqmzDU+XJ/MM8UQc3HBuPPADWJrKP5hhcr1eznnXdeZVttVyb0juK9ROcLvrDVzIc9+PCgCzFN0AKBRK84nlme4a5sN84LG/HuITBPc8yXvvSlOCTCxAkru1ULOhVs9sUvhf322TfWuP5jhZjGv2yfffeNtf26F8kHu0mEd0WwHYF7iOcQ52V6cwkqA05bIQapSeRe4t1PxQB2Io70jKPVqJRG9CBwKLTpcq3eR7Rf8oJFCIEenjKiFyTnj/jhK5zaHQaLo+cbzmvf+ta3ouChKh3HN9KnL1bmywaC570VL1GqzT/20f8XLvrjhZV76MnHnwhf3eIrYa899gxvzv4/DBTHDCkTukewCc8XhQnV5Pj0yJGZNBQ6++23X3yp4kOm5jAC25WtSVXPEs8ivd1wMqV2FbAl7zNs9Zvf/KbyscKgjjTh//a3v41pZPOuSPZ9RTMoXaq32Xqb8ODfHohpaMJasmjxihvsn2HRgoWxxnXdj68THnrgwbie2h+GmTj44IMrNlR+XfldxrM1aNCgeP/wTqcWBzh3PW/4uFLzQ+0hAf87ehPi00PHgkb26yyF6OEG5mJeeOHK9luc/4455pjYHo6fSlptrIepbOi8sZNeAFnoss4AVmkBxHZ6Qch+ZUJd1p9/9rmw8447xZfqrw4+JI4Bst03to3LfS79U1i+dEUhvkIcvd9FC6FqqGDSM8X0xBNPjDWGjMcjRo4cGZ9NxNDhhx8em7h4yeLPwrqyoeeImh6at/i6Vk0PzyfPIM1/jNPzy1/+MpxwwgnRmZmCn1ptIE1XfZdhHwk6fE4OPPDAWPP1zR2+GY793THh14cdHn5z+K/DQd0ODJMmruyZde/d98Tani9vtnk464wzw7dWpP3SF75YadriPpUw76piERDP1Nww2CzvdA0jgfjDjtV8duiAQPOWxulpVEpT08NDglMgDoA777xzrKo7/vjj/60HCZSx8OZ8sYGmBB58XrpaZvRXbnypfOJSW5XNZoBvAD4CdH9lPJBzz+kRtt3mG3H8D8YJobv6siUre0ggejSYYZnQfcG9wv00dOjQ+KJVkwJQ8CB0DjrooOiTQq3PAQccEJtWhwwZ0pSqPGAzAu+svn37RqFIF3Y9c8A6aqkpuBA82I8mC57bNF1XheYphB2/VMD3kCb5H/7wh7EJa/999wvf3es7sZaVmp8PVjyfQC0PNT4ML0GX9g81R6+wlz7ourLooZaeJmYEDoHOKgwEynPHvLqkq7ZV73h6DB5xxBGVcXwa9X1fGtHDheNG1o0tPwJeDlxYfRUplA29JAlaVsA2BL4weRCYl+0IzCuUDUSManHi8oqX69LFS8LihYtWxP+rRozBCQllEz3cEzxfTLl/VJPIPZQ+k0xZhyjSvbZw4cJYoBFfNrAXduH5wha8r7CRnj/NAzZDABEPbCv7sn1XhPPivtD5cb4qpHkWF8ybH95d8VzywcFzRzPXB021sqxnWc8s6B7URx7LXRXOT/bS86b7h+eNedIQ9KySlnk9r438ri+N6BHZm1kPDtP0RVNWdO5MdWNzo6cQn970zKfpS0XTueM/kEX+O9glNmthnxKaSPcGz1b6/Om+yT6TkN5L2fuvTGAfIZswlT1TO0GavpptuwKcG/dF9vyrQrJmkmIn2Y48u+o91xp7yQ5MlT5rH803IqUTPcYYY4wpJxY9xhhjjCkFFj3GGGOMKQUWPcYYY4wpBRY9xrQCRrpllNLOBoOI8TuC8ePHN8WsOtp6LHSR/chHPlL4OaxKW40bNy52+eUYGGGZ4+iMcIyd4V4ypigsekwpoZBtKVx00UVNqS16WoNFTz6IHMaQ4TcRTHV/dUb0KwuO2ZiuiEWPKR0UfrzYmYqsyGHeL/7Ghmu8qqHmBKGTwt/QO6voAQkfaqeM6WpY9JjS8eCDD/7bCz0reiBbWJnGAUG7qoUF4oGapVRcQ2cXPaBaMc7BmK6ERY8xK8gTPaYxUU3FqhYW3E95wrkRRA9wnH4mTFfDoseYFTQneqgZoqmLQgAoVGm22GSTTeI6fH3YnmX8U/hKVsFGXPZLH58SFcp8TbdUsJCefEhL/qlvETVWaeHEvlivGgb5kOQdB9sQz3qOR//cEel6pi35wrT1WLLbiZb2X+34ZVsFXbdq+9G11H7S9a09hzyyeQmOgTy4jzTPMWfza+64tB1BaFnnmx47tiEP9gPN3VNC9jWmK2HRY8wKKCzyCiigYEgLE9IpjnkKFwowCggVTiwTT7rUN4jChgKG9UDBRj7Z5rYUFUxA3joOBFd6HKBCWXHVjoNjUEGrYyeNYL2OifVsS56kz6Otx5K3HbS0/5aOX6JAVNsP86ng0PUgf2itPbOQhm3YbxYdW3P5tXRcwHriBHkRp/sjPXbuO+wpGzHNu6dS2IZtdQzGdAUseoxZAS93Xv7VYH1aMJCWuLRQU1wK26TbqaDKhrxCR7A+3U9aOBLP+vTYyYu4lPQ4VCCnhVlaIFJ4sj4vNGejthwLZLdraf8tHT/k7bfafiSuRFZgteYcsmhfTLO0lF9HHpfSkGcKcemx5Qm45s7BmEblw0+MMSWFl3tzBTrr08KEtNkCQXEp2UKoLYWIhBLTbEGogik9dhV0KelxaJtsQSi0vlbaciyQ3a6l/bd0/JC332r7YZqiGg7Ft+YcslTLG1rKryOPKy8NNHdPiebOwZhG5d+fBmNKCC/3tLDOwvq0MCFttkBQXEq2EGppP3lQuLMNTThsT0GlAl8FU5pnXkGXHoe26ejCri3HAtntWtq/1lc7fsjbb7X9ICZSsvtvzTlkyeaR0lJ+HXlceWmguXtKNHcOxjQq//40GFNCeLmnhXUW1qeFCWmzBYLiUrKFkAoZfDRUyDDNa14Q6Tr5dmi/KpjSY88r6NLjwJeD9TQHpcdPIYuQUPMR69OCl7TsvxptORbIbtfS/ls6fsjbb7X94PuSQh7E6/q05hyyKO+scIGW8mvtceHf09Jx5e0LmrunhOzF8RjTVfj3p8GYkqFCNHUSTaGQYT1fw0IFTlqoyedChRKwTbod6UmTDc3VWrBeYkPHKidU5Zfn4NrccaROrgQEBIIsW6BmQ3MFYFuPJStGoKX9t3T85EU8yzqevOPTfmRf8ufY0mNpzTnkwfGk+YjW5Nea49I5ci+QF2klqiV8tK8sad7Ze0qQP/kZ05Ww6DGlRl/Cach+8abrSK/CRoH02XxUkKdBIHBUOFUrGFNYT6BgJ0ggZfdBmuxxQLqsOIkB8iOO7bKFXrqewjMVeFnacyzaNmuH5vbf0vEzzzrsy3ze8Qnm0+shMQCtPYc8ZIOUWvJr7rgAGyg/nT9TxLfmlSfbp5A3ARsR8kQ3whIbG9OVqP7EGmNMHZAgYdqVQJQgKBqxeYhjbtRjN6Y5LHqMMasUiZ60pqarQA0KtVQIoEaCWp5szZIxXQGLHmNM3aGpSs0qzCMMuio0NzWK8OEYETypo7MxXQmLHmNM3aF2B9FDDQ+FbKPVhNQKwq4Rak44RtfwmK6MRY8xxhhjSoFFjzHGGGNKgUWPMcYYY0qBRY8xxhhjSoFFjzHGGGNKgUWPMcYYY0qBRY8xxhhjSoFFjzHGGGNKgUWPMcY0CPwAtKNGr2bAREbE1q8y+AGpMV0dix5TV3ix6s/PzQXTmGT/Zk7gb9958QqMzEwaRgKu58jM6Z/Imdb67y+JBbavl2DoSNHDryZuueWWysjYFj2mDLh0MXWFF206zL1EkOCvzptssknhf3emcKWg6yx0tuNpL1xnrmv2OvLLiWw8gkjxXPt6/HgUe1PY615EwLDcGtFFGoQHx8p2q/pP5NTYtEWw6P9aEqQWPaYMWPSYupL9kWFW9AAFES/iIqGw6kwio7MdT3vJu65QLR6wAes6qiajObgPs/vB/tn7M4sET2f6XxjHXKtgUdMWWPSYMmHRY1YpzRWCRUFNgppUOgOd7Xg6graIHsAGrFeBXBTYO1vII7aJbw7EDjU8nUXwSCjWKlgQSjoHix5TJix6zCqluUKQlzEvZwpCXu4USPg0AC9s1hHH9qRJm0X4kqVwYh1BX/A0RWgbBY4h3Rf5aFvtTwWi0qc0dyxpvsxTS6A0UO14OpJ//vOfTXMdS3P5VruuzV1vUCGOuBDYUs1fBOyZig7WY0/WqcmpObA5ablHUlT4p/dRCvHaf7q/bD4pypOg6yobEFgPHDN5so57TfeftgGOm/uR+wXYr/JJ89P9yDJT0mk/gnihY9S+0mNWnlCrnY3pjFj0mFWKCoA8JAZ4wfLC5UWtwpCpXsYUBvKx0DLbyV+DKcvpS5plCQ/QvshHhZi2S/dFoUMc+xDNHUt6DjoeFVbNHU97mDt3bnj77bdjWLZsWXj33XfD8uXLY2HIujfffDMuEz9v3rwYN3/+/PCPf/wjvP/++zGOQPrFixdHcUM+pCMsWLAgfPDBBzGObd57772mPf+Late1uesNKnBlC+yJfWVv1mNTFdocY7qs9eRRbT/ah66ZqBYvdOxcN/ara01cNaEEut4SFUAe2hchvf+0/+y9hh1YJggdc5o39xlpgW2599Jz4njSey+bh2yu5wDaYmdjOiO+W80qpaVCkHUUBCkqRPICL2N9kauwAJbTgoHlrMioFpdupwJChUhLxwLMt5RvXpq2gAA588wzwy677BL22WefcP3118d4jnO//fYL3/rWt0LPnj1juqeffjoceuihYffddw8HH3xweP7556OIOeOMM8Kuu+4a9t5773DNNdfE7W+66aZwwAEHhN122y2cc845UfwghsgH8ZOl2nVt6XrLvrKFCv68ANnrAWzTnC3ztoFq8YI8s/lyj7FNWnOSRfk2dx+1Jg2wf+JE3nbMI1oQKoDASfPgWLUO0jxUm5Ouh7xjacnOxnRGqr99jKkDvGjTl3gW1mVfrGzTmpctBRJp+dLNFgx5+VaLS7fLvvxbcyytyTcvTVtAtDz00EPh2muvDTfffHN45plnYq3Oyy+/HJevu+66MGnSpFhTM2fOnHDrrbeGG264Idx5551RyFD7c++994Ybb7wxhhkzZkRx88ILL0ThxPYTJkwIS5YsiWkVsk1dnBvnlKVavFANiEQENkntlCWvMG5pHxLF6TagvKrV2nAsedcIUd7ctVO+6Xlkj7s1aYD9ECfytpMQV81MKv4hK9CUB0KJbbLpIe9YWrKzMZ0R37FmldLSi5N12QKFbXg5Z79GU/gKVZOSvsbTgiEv32px6XbZl39rjqU1+ealaQsIkCwInCyIozyfHJq3sixatKhp7sOQL+nJK7sPzo1zylItXmAD1qv5heWW7ILoUM0G15rr3tI2XLPU/qBrWQ3EAnlnYV9qTspD90y6v+x91Jo0IPuIvO2AeI6JdQTZE0GUNm2B8pDoydasirbY2ZjOhkWPWaXwsk5f4llYl32xqjaAl3D6VU5eLMsXJxUiLKcFQ16+1eKaK4haOhZoTb55adoCAiSthQGaoJYuXRrnESekQaxIqGgd6SRgmGeq9EwlkphX7Y7SdERNj2yZ2gGhQVy2xiIVGdiZbSiwlbY5EQqkydqbZeKroRoUXXtB4Z8VEikcC9s1dx9pubk0wDESJ/K2Y162Ysq9qXPNs02aB7bEjnl2aIudjelsWPSYVYq+RvNeniossoUT8CJnXRr0Fc7Lm2Ve0uShwpR4Ci4gT/JgPfHaF3GCAoM4ao2ECj7lA80dS16+ikvzzR5PW0F8pIJFjswSKaqZkcAhTvEE5okHtlcaYKp8lVbLhBQKRM4xFSqg653GU+gqXjYQpFMhmwYVyqTF1uk2rYH05CuxglBmOT0urkM2TteJOPLgONJrWw2OWUKN85V9JJh0X7X2XkvPV9txv5MXx61jBParfctuKdl9kwfnnaZtq52N6WxY9JhVgr4u05AVN4rnBayXtuDlq4KSwDwvfeBlzwtaebJMIUCc0kgIsZ68lI/issdHHIVJGidx0tyxpOmr5QvZ42lUql3XvHgFXV9skAe2VGGvwlg2qpYv6arlJ9J8OUZdM5EnetivBAshPZbmkJAgkC/HLcHDryCUH4H1efcax5jGCR2PRAtpORel1z2FuMnaJGs/HVtLcQqtsbMxnQmLHmNMh/L2isLwn3PmNC2F8M+FC8Oigw+O8cuGDWuK7Zh4CvMdt9wy9F8RR/xPV4S0QP7HhAlh6cUXx7Sm7WBnCcRswM7GNAoWPcaYDgVhsvTSS5uWViwfemhYdPzxYdlll4U5G23UFNsx8dRoPLHLLv8WTyHd48QTw9wvfjEsGzEixpm2g53zanSwc9okZ0xnx6LHGNOhvHfPPeGdFV//S3r2DMsuv7zDhQ4o/tiPfjS8vPrqlaYp4t8+8shw8wrR9co3vhEWn3JKjDftg9oc+Q0JBA9CiKYvYxoFix5jjDHGlAKLHmOMMcaUAoseY4wxxpQCix5jjDHGlIAQ/j/JFV12ays6LwAAAABJRU5ErkJggg==" /></p><p>&nbsp;</p><p>Figure 1 Glucose infusion rate profile, smoothed, steady state - Mean profile 0-24 hours - IDeg 100 units/mL 0.6 units/kg - Trial 1987</p><p><strong>&nbsp;</strong></p><p>The duration of action of Tresiba is beyond 42 hours within the therapeutic dose range. Steady state will occur after 2&ndash;3 days of dose administration.</p><p><u>The day-to-day variability, expressed as the coefficient of variation, in glucose-lowering effect during one dosing interval of 0-24 hours at steady state (AUC</u><u>GIR,&tau;,SS) is 20% for insulin degludec, which is significantly lower than for insulin glargine (100 units/mL).</u></p><p>&nbsp;</p><p>The total glucose-lowering effect of Tresiba increases linearly with increasing doses.</p><p>&nbsp;</p><p>The total glucose-lowering effect is comparable for Tresiba 100 units/mL and 200 units/mL after administration of the same doses of the two products.</p><p>&nbsp;</p><p>There is no clinically relevant difference in the pharmacodynamics of this medicinal product between elderly and younger adult patients.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>11 multinational clinical trials of 26 or 52 weeks&rsquo; duration were conducted as controlled, open-label, randomised, parallel, treat-to-target trials exposing 4,275 patients to Tresiba (1,102 in type 1 diabetes mellitus and 3,173 in type 2 diabetes mellitus).</p><p>&nbsp;</p><p>&nbsp;</p><p>In the open-label trials the effect of Tresiba was tested in patients with type 1 diabetes mellitus (Table 2), in insulin na&iuml;ve patients (insulin initiation in type 2 diabetes mellitus, Table 3) and in previous insulin users (insulin intensification in type 2 diabetes mellitus, Table 4) with fixed as well as flexible dosing time (Table 5), and the reduction in HbA1c from baseline to end of trial was confirmed to be non-inferior in all trials against all comparators (insulin detemir and insulin glargine (100 units/mL)). While improvements in HbA1c were non-inferior compared to other insulin products, against sitagliptin Tresiba was statistically significantly superior in reducing HbA1c (Table 4).</p><p>&nbsp;</p><p>In a prospectively planned meta-analysis across seven open-label treat-to-target confirmatory trials in patients with type 1 and type 2 diabetes mellitus, Tresiba was superior in terms of a lower number of treatment-emergent confirmed hypoglycaemic episodes (driven by a benefit in type 2 diabetes mellitus, see Table 1) and nocturnal confirmed hypoglycaemic episodes compared to insulin glargine (100 units/ml) (administered according to label). The reduction in hypoglycaemia was achieved at a lower average FPG level with Tresiba than with insulin glargine.</p><p>&nbsp;</p><p>Table 1 Hypoglycaemia meta-analysis outcomes</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Confirmed hypoglycaemia<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Estimated risk ratio (Insulin degludec/Insulin glargine)</p></td><td style="vertical-align:top"><p>Total</p></td><td style="vertical-align:top"><p>Nocturnal</p></td></tr><tr><td style="vertical-align:top"><p>Type 1 + Type 2 diabetes mellitus (pooled)</p></td><td style="vertical-align:top"><p>0.91*</p></td><td style="vertical-align:top"><p>0.74*</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance period <sup>b</sup></p></td><td style="vertical-align:top"><p>0.84*</p></td><td style="vertical-align:top"><p>0.68*</p></td></tr><tr><td style="vertical-align:top"><p>Geriatric patients &ge;65 years</p></td><td style="vertical-align:top"><p>0.82</p></td><td style="vertical-align:top"><p>0.65*</p></td></tr><tr><td style="vertical-align:top"><p>Type 1 diabetes mellitus</p></td><td style="vertical-align:top"><p>1.10</p></td><td style="vertical-align:top"><p>0.83</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance period <sup>b</sup></p></td><td style="vertical-align:top"><p>1.02</p></td><td style="vertical-align:top"><p>0.75*</p></td></tr><tr><td style="vertical-align:top"><p>Type 2 diabetes mellitus</p></td><td style="vertical-align:top"><p>0.83*</p></td><td style="vertical-align:top"><p>0.68*</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance period <sup>b</sup></p></td><td style="vertical-align:top"><p>0.75*</p></td><td style="vertical-align:top"><p>0.62*</p></td></tr><tr><td style="vertical-align:top"><p>Basal only therapy in previously insulin-na&iuml;ve</p></td><td style="vertical-align:top"><p>0.83*</p></td><td style="vertical-align:top"><p>0.64*</p></td></tr></tbody></table><p>*Statistically significant <sup>a</sup> Confirmed hypoglycaemia was defined as episodes confirmed by plasma glucose &lt;3.1 mmol/L or by the patient needing third party assistance. Nocturnal confirmed hypoglycaemia was defined as episodes between midnight and 6 a.m. <sup>b</sup> Episodes from week 16.</p><p>&nbsp;</p><p>There is no clinically relevant development of insulin antibodies after long-term treatment with Tresiba.</p><p>&nbsp;</p><p>Table 2 Results from open-label clinical trials in type 1 diabetes mellitus</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>52 weeks of treatment</p></td><td colspan="2" style="vertical-align:top"><p>26 weeks of treatment</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Insulin glargine</strong></p><p><strong>(100 units/mL)<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Insulin detemir<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>472</strong></p></td><td style="vertical-align:top"><p><strong>157</strong></p></td><td style="vertical-align:top"><p><strong>302</strong></p></td><td style="vertical-align:top"><p><strong>153</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>HbA</strong><strong>1c </strong>(%)</p></td></tr><tr><td style="vertical-align:top"><p>End of trial</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>7.3</p></td></tr><tr><td style="vertical-align:top"><p>Mean change</p></td><td style="vertical-align:top"><p>-0.40</p></td><td style="vertical-align:top"><p>-0.39</p></td><td style="vertical-align:top"><p>-0.73</p></td><td style="vertical-align:top"><p>-0.65</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.01 [-0.14; 0.11]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.09[-0.23; 0.05]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>FPG </strong>(mmol/L)</p></td></tr><tr><td style="vertical-align:top"><p>End of trial</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>8.9</p></td></tr><tr><td style="vertical-align:top"><p>Mean change</p></td><td style="vertical-align:top"><p>-1.27</p></td><td style="vertical-align:top"><p>-1.39</p></td><td style="vertical-align:top"><p>-2.60</p></td><td style="vertical-align:top"><p>-0.62</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.33 [-1.03; 0.36]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -1.66 [-2.37; -0.95]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Rate of hypoglycaemia </strong>(per Patient year of exposure)</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>0.21</p></td><td style="vertical-align:top"><p>0.16</p></td><td style="vertical-align:top"><p>0.31</p></td><td style="vertical-align:top"><p>0.39</p></td></tr><tr><td style="vertical-align:top"><p>Confirmed<sup>2</sup></p></td><td style="vertical-align:top"><p>42.54</p></td><td style="vertical-align:top"><p>40.18</p></td><td style="vertical-align:top"><p>45.83</p></td><td style="vertical-align:top"><p>45.69</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 1.07 [0.89; 1.28]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.98 [0.80; 1.20]</em></p></td></tr><tr><td style="vertical-align:top"><p>Nocturnal confirmed<sup>2</sup></p></td><td style="vertical-align:top"><p>4.41</p></td><td style="vertical-align:top"><p>5.86</p></td><td style="vertical-align:top"><p>4.14</p></td><td style="vertical-align:top"><p>5.93</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.75 [0.59; 0.96]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.66 [0.49; 0.88]</em></p></td></tr></tbody></table><p>&nbsp;</p><p>1 In a once-daily regimen + insulin aspart to cover mealtime insulin requirements</p><p>2 Confirmed hypoglycaemia was defined as episodes confirmed by plasma glucose &lt;3.1 mmol/L or by the patient needing third party assistance. Nocturnal confirmed hypoglycaemia was defined as episodes between midnight and 6 a.m.</p><p>&nbsp;</p><p>Table 3 Results from open-label clinical trials in insulin na&iuml;ve type 2 diabetes mellitus (insulin initiation)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>52 weeks of treatment</p></td><td colspan="2" style="vertical-align:top"><p>26 weeks of treatment</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Insulin glargine</strong></p><p><strong>(100 units/mL)<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Insulin glargine</strong></p><p><strong>(100 units/mL)<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>773</strong></p></td><td style="vertical-align:top"><p><strong>257</strong></p></td><td style="vertical-align:top"><p><strong>228</strong></p></td><td style="vertical-align:top"><p><strong>229</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>HbA</strong><strong>1c </strong>(%)</p></td></tr><tr><td style="vertical-align:top"><p>End of trial</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>6.9</p></td></tr><tr><td style="vertical-align:top"><p>Mean change</p></td><td style="vertical-align:top"><p>-1.06</p></td><td style="vertical-align:top"><p>-1.19</p></td><td style="vertical-align:top"><p>-1.30</p></td><td style="vertical-align:top"><p>-1.32</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: 0.09 [-0.04; 0.22]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: 0.04 [-0.11; 0.19]</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>FPG </strong>(mmol/L)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>End of trial</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>6.3</p></td></tr><tr><td style="vertical-align:top"><p>Mean change</p></td><td style="vertical-align:top"><p>-3.76</p></td><td style="vertical-align:top"><p>-3.30</p></td><td style="vertical-align:top"><p>-3.70</p></td><td style="vertical-align:top"><p>-3.38</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.43 [-0.74; -0.13]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.42 [-0.78; -0.06]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Rate of hypoglycaemia </strong>(per patient year of exposure)</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.02</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Confirmed<sup>2</sup></p></td><td style="vertical-align:top"><p>1.52</p></td><td style="vertical-align:top"><p>1.85</p></td><td style="vertical-align:top"><p>1.22</p></td><td style="vertical-align:top"><p>1.42</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.82 [0.64; 1.04]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.86 [0.58; 1.28]</em></p></td></tr><tr><td style="vertical-align:top"><p>Nocturnal confirmed<sup>2</sup></p></td><td style="vertical-align:top"><p>0.25</p></td><td style="vertical-align:top"><p>0.39</p></td><td style="vertical-align:top"><p>0.18</p></td><td style="vertical-align:top"><p>0.28</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.64 [0.42; 0.98]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.64 [0.30; 1.37]</em></p></td></tr></tbody></table><p>1 Once-daily regimen + metformin &plusmn; DPP-IV inhibitor</p><p>2 Confirmed hypoglycaemia was defined as episodes confirmed by plasma glucose &lt;3.1 mmol/L or by the patient needing third party assistance. Nocturnal confirmed hypoglycaemia was defined as episodes between midnight and 6 a.m.</p><p>&nbsp;</p><p>Table 4 Results from open-label clinical trials in type 2 diabetes mellitus: left &ndash; prior basal insulin users, right &ndash; insulin na&iuml;ve</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>52 weeks of treatment</p></td><td colspan="2" style="vertical-align:top"><p>26 weeks of treatment</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Insulin glargine</strong></p><p><strong>(100 units/mL)<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>2</sup></strong></p></td><td style="vertical-align:top"><p><strong>Sitagliptin<sup>2</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>744</strong></p></td><td style="vertical-align:top"><p><strong>248</strong></p></td><td style="vertical-align:top"><p><strong>225</strong></p></td><td style="vertical-align:top"><p><strong>222</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>HbA</strong><strong>1c </strong>(%)</p></td></tr><tr><td style="vertical-align:top"><p>End of trial</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>7.7</p></td></tr><tr><td style="vertical-align:top"><p>Mean change</p></td><td style="vertical-align:top"><p>-1.17</p></td><td style="vertical-align:top"><p>-1.29</p></td><td style="vertical-align:top"><p>-1.56</p></td><td style="vertical-align:top"><p>-1.22</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: 0.08 [-0.05; 0.21]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.43 [-0.61; -0.24]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>FPG </strong>(mmol/L)</p></td></tr><tr><td style="vertical-align:top"><p>End of trial</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>6.2</p></td><td style="vertical-align:top"><p>8.5</p></td></tr><tr><td style="vertical-align:top"><p>Mean change</p></td><td style="vertical-align:top"><p>-2.44</p></td><td style="vertical-align:top"><p>-2.14</p></td><td style="vertical-align:top"><p>-3.22</p></td><td style="vertical-align:top"><p>-1.39</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.29 [-0.65; 0.06]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -2.17 [-2.59; -1.74]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Rate of hypoglycaemia </strong>(per patient year of exposure)</p></td></tr><tr><td style="vertical-align:top"><p>Severe hypoglycaemia</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.05</p></td><td style="vertical-align:top"><p>0.01</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Confirmed<sup>3</sup></p></td><td style="vertical-align:top"><p>11.09</p></td><td style="vertical-align:top"><p>13.63</p></td><td style="vertical-align:top"><p>3.07</p></td><td style="vertical-align:top"><p>1.26</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.82 [0.69; 0.99]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 3.81 [2.40; 6.05]</em></p></td></tr><tr><td style="vertical-align:top"><p>Nocturnal confirmed<sup>3</sup></p></td><td style="vertical-align:top"><p>1.39</p></td><td style="vertical-align:top"><p>1.84</p></td><td style="vertical-align:top"><p>0.52</p></td><td style="vertical-align:top"><p>0.30</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.75 [0.58; 0.99]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 1.93 [0.90; 4.10]</em></p></td></tr></tbody></table><p>1 Once-daily regimen + insulin aspart to cover mealtime insulin requirements &plusmn; metformin &plusmn; pioglitazone</p><p>2 Once-daily regimen &plusmn; metformin SU/glinide &plusmn; pioglitazone</p><p>3 Confirmed hypoglycaemia was defined as episodes confirmed by plasma glucose &lt;3.1 mmol/L or by the patient needing third party assistance. Nocturnal confirmed hypoglycaemia was defined as episodes between midnight and 6 a.m.</p><p>&nbsp;</p><p>Table 5 Results from an open-label clinical trial with flexible dosing of Tresiba in type 2 diabetes mellitus</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>26 weeks of treatment</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>1</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Tresiba Flex<sup>2</sup></strong></p></td><td style="vertical-align:top"><p><strong>Insulin glargine</strong></p><p><strong>(100 units/mL)<sup>3</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>228</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>229</strong></p></td><td style="vertical-align:top"><p><strong>230</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>HbA</strong><strong>1c (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>End of trial</p></td><td style="vertical-align:top"><p>7.3</p></td><td colspan="2" style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>7.1</p></td></tr><tr><td style="vertical-align:top"><p>Mean change</p></td><td style="vertical-align:top"><p>-1.07</p></td><td colspan="2" style="vertical-align:top"><p>-1.28</p></td><td style="vertical-align:top"><p>-1.26</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.13 [-0.29; 0.03]<sup>5</sup></em></p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: 0.04 [-0.12; 0.20]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>FPG (mmol/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p>End of trial</p></td><td style="vertical-align:top"><p>5.8</p></td><td colspan="2" style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>6.2</p></td></tr><tr><td style="vertical-align:top"><p>Mean change from</p><p>baseline</p></td><td style="vertical-align:top"><p>-2.91</p></td><td colspan="2" style="vertical-align:top"><p>-3.15</p></td><td style="vertical-align:top"><p>-2.78</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.05 [-0.45; 0.35]<sup>5</sup></em></p></td><td colspan="2" style="vertical-align:top"><p><em>Difference: -0.42 [-0.82; -</em></p><p><em>0.02]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Rate of hypoglycaemia </strong>(per patient year of exposure)</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>0.02</p></td><td colspan="2" style="vertical-align:top"><p>0.02</p></td><td style="vertical-align:top"><p>0.02</p></td></tr><tr><td style="vertical-align:top"><p>Confirmed<sup>4</sup></p></td><td style="vertical-align:top"><p>3.63</p></td><td colspan="2" style="vertical-align:top"><p>3.64</p></td><td style="vertical-align:top"><p>3.48</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 1.10 [0.79; 1.52]<sup>6</sup></em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 1.03 [0.75; 1.40]</em></p></td></tr><tr><td style="vertical-align:top"><p>Nocturnal confirmed<sup>4</sup></p></td><td style="vertical-align:top"><p>0.56</p></td><td colspan="2" style="vertical-align:top"><p>0.63</p></td><td style="vertical-align:top"><p>0.75</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 1.18 [0.66; 2.12]<sup>6</sup></em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.77 [0.44; 1.35]</em></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>1 Once-daily regimen (with main evening meal) + one or two of the following oral antidiabetes agents: SU, metformin or DPP-4 inhibitor</p><p>2 Flexible once-daily regimen (intervals of approximately 8&ndash;40 hours between doses) + one or two of the following oral antidiabetes agents SU, metformin or DPP-4 inhibitor</p><p>3 Once-daily regimen + one or two of the following oral antidiabetes agents: SU, metformin or DPP-4 inhibitor</p><p>4 Confirmed hypoglycaemia was defined as episodes confirmed by plasma glucose &lt;3.1 mmol/L or by the patient needing third party assistance. Nocturnal confirmed hypoglycaemia was defined as episodes between midnight and 6 a.m.</p><p>5 The difference is for Tresiba Flex &ndash; Tresiba</p><p>6 The ratio is for Tresiba Flex/Tresiba.</p><p>&nbsp;</p><p>In a 104-week clinical trial, 57% of patients with type 2 diabetes treated with Tresiba (insulin degludec) in combination with metformin achieved a target HbA1c &lt;7.0%, and the remaining patients continued in a 26-week open-label trial and were randomised to add liraglutide or a single dose of insulin aspart (with the largest meal). In the insulin degludec + liraglutide arm, the insulin dose was reduced by 20% in order to minimise the risk of hypoglycaemia. Addition of liraglutide resulted in a statistically significantly greater reduction of HbA1c (-0.73% for liraglutide vs -0.40% for comparator, estimated means) and body weight (-3.03 vs 0.72 kg, estimated means). The rate of hypoglycaemic episodes (per patient year of exposure) was statistically significantly lower when adding liraglutide compared to adding a single dose of insulin aspart (1.0 vs 8.15; ratio: 0.13; 95% CI: 0.08 to 0.21).</p><p>&nbsp;</p><p>Furthermore, two 64-week controlled, double-blind, randomised, cross-over, treat-to-target trials were conducted in patients with at least one risk factor for hypoglycaemia and with type 1 diabetes mellitus (501 patients) or type 2 diabetes mellitus (721 patients). Patients were randomised to either Tresiba or insulin glargine (100 units/mL) followed by cross-over. The trials evaluated the rate of hypoglycaemia upon treatment with Tresiba compared to insulin glargine (100 units/mL) (see Table 6).</p><p>&nbsp;</p><p>Table 6 Results from the double-blind, cross-over clinical trials in type 1 and type 2 diabetes mellitus</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Type 1 diabetes mellitus</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Type 2 diabetes mellitus</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Insulin glargine (100 units/mL)<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tresiba<sup>2</sup></strong></p></td><td style="vertical-align:top"><p><strong>Insulin glargine (100 units/mL)<sup>2</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>501</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>721</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>HbA</strong><strong>1c </strong>(%)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td colspan="2" style="vertical-align:top"><p>7.6</p></td><td colspan="2" style="vertical-align:top"><p>7.6</p></td></tr><tr><td style="vertical-align:top"><p>End of treatment</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>7.0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>FPG </strong>(mmol/L)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td colspan="2" style="vertical-align:top"><p>9.4</p></td><td colspan="2" style="vertical-align:top"><p>7.6</p></td></tr><tr><td style="vertical-align:top"><p>End of treatment</p></td><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>6.0</p></td><td style="vertical-align:top"><p>6.1</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Rate of severe hypoglycaemia<sup>3</sup></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Maintenance period<sup>4</sup></p></td><td style="vertical-align:top"><p>0.69</p></td><td style="vertical-align:top"><p>0.92</p></td><td style="vertical-align:top"><p>0.05</p></td><td style="vertical-align:top"><p>0.09</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.65 [0.48; 0.89]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.54 [0.21; 1.42]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Rate of severe or BG confirmed symptomatic hypoglycaemia<sup>3,5</sup></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Maintenance period<sup>4</sup></p></td><td style="vertical-align:top"><p>22.01</p></td><td style="vertical-align:top"><p>24.63</p></td><td style="vertical-align:top"><p>1.86</p></td><td style="vertical-align:top"><p>2.65</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.89 [0.85; 0.94]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.70 [0.61; 0.80]</em></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Rate of severe or BG confirmed symptomatic nocturnal hypoglycaemia<sup>3.5</sup></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Maintenance period<sup>4</sup></p></td><td style="vertical-align:top"><p>2.77</p></td><td style="vertical-align:top"><p>4.29</p></td><td style="vertical-align:top"><p>0.55</p></td><td style="vertical-align:top"><p>0.94</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.64 [0.56; 0.73]</em></p></td><td colspan="2" style="vertical-align:top"><p><em>Ratio: 0.58 [0.46; 0.74]</em></p></td></tr></tbody></table><p>1 In a once-daily regimen + insulin aspart to cover mealtime insulin requirements</p><p>2 In a once-daily regimen &plusmn; OADs (any combination of metformin, dipeptidyl peptidase-4 inhibitor, alpha-glucosidase inhibitor, thiazolidinediones, and sodium glucose cotransporter-2 inhibitor)</p><p>3 Per patient year of exposure</p><p>4 Episodes from week 16 in each treatment period</p><p>5 Blood glucose (BG) confirmed symptomatic hypoglycaemia was defined as episodes confirmed by a plasma glucose value of less than 3.1 mmol/L, with symptoms consistent with hypoglycaemia. Nocturnal confirmed hypoglycaemia was defined as episodes between midnight and 6 a.m.</p><p>&nbsp;</p><p><u>Cardiovascular evaluation</u></p><p>DEVOTE was a randomised, double-blind, and event-driven clinical trial with a median duration of 2 years comparing the cardiovascular safety of Tresiba versus insulin glargine (100 units/mL) in 7,637 patients with type 2 diabetes mellitus at high risk of cardiovascular events.</p><p>The primary analysis was time from randomisation to first occurrence of a 3-component major adverse cardiovascular event (MACE) defined as cardiovascular death, non-fatal myocardial infarction, or</p><p>non-fatal stroke. The trial was designed as a non-inferiority trial to exclude a pre-specified risk margin of 1.3 for the hazard ratio (HR) of MACE comparing Tresiba to insulin glargine. The cardiovascular safety of Tresiba as compared to insulin glargine was confirmed (HR 0.91 [0.78; 1.06]) (Figure 2).</p><p>Results from subgroup analyses (e.g. sex, diabetes duration, CV risk group and previous insulin regimen) was aligned with the primary analysis.</p><p><img alt="" width="300" height="121" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>N: Number of subjects with a first EAC confirmed event during trial. %: Percentage of subjects with a first EAC confirmed event relative to the number of randomised subjects. EAC: Event adjudication committee. CV: Cardiovascular. MI: Myocardial infarction. CI: 95% confidence interval.</p><p>Figure 2 Forest plot of analysis of the composite 3-point MACE and individual cardiovascular endpoints in DEVOTE</p><p><strong>&nbsp;</strong></p><p>At baseline, HbA1c was 8.4% in both treatment groups and after 2 years HbA1c was 7.5% both with Tresiba and insulin glargine.</p><p>Tresiba was superior compared to insulin glargine in terms of a lower rate of severe hypoglycaemic events and a lower proportion of subjects experiencing severe hypoglycaemia. The rate of nocturnal severe hypoglycaemia was significantly lower for Tresiba compared to insulin glargine (Table 7).</p><p>&nbsp;</p><p>Table 7 Results from DEVOTE</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Tresiba</strong><sup>1</sup></p></td><td style="vertical-align:top"><p><strong>Insulin glargine (100 units/mL)</strong><sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p>3,818</p></td><td style="vertical-align:top"><p>3,819</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Rate of hypoglycaemia </strong>(per 100 patient years of observation)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>3.70</p></td><td style="vertical-align:top"><p>6.25</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Rate ratio: 0.60 [0.48; 0.76]</em></p></td></tr><tr><td style="vertical-align:top"><p>Nocturnal severe<sup>2</sup></p></td><td style="vertical-align:top"><p>0.65</p></td><td style="vertical-align:top"><p>1.40</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Rate ratio: 0.47 [0.31; 0.73]</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Proportions of patients with hypoglycaemia </strong>(percent of patients)</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>6.6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Odds ratio: 0.73 [0.60; 0.89]</em></p></td></tr></tbody></table><p><sup>1</sup>In addition to standard of care for diabetes and cardiovascular disease</p><p><sup>2</sup> Nocturnal severe hypoglycaemia was defined as episodes between midnight and 6 a.m.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Tresiba has been studied in an open-label, randomised, active controlled clinical trial, in which pregnant women with type 1 diabetes mellitus were treated within a basal-bolus treatment regimen with Tresiba or insulin detemir as basal insulin, both in combination with insulin aspart as meal time insulin (EXPECT).</p><p>&nbsp;</p><p>Tresiba was non-inferior to insulin detemir as measured by HbA1c at last planned HbA1c visit prior to&nbsp;delivery after GW 16. Moreover, no difference between treatment groups was observed for glycaemic control (change in HbA1c, FPG and PPG) during pregnancy (Table 8).</p><p>&nbsp;</p><p>No clinically relevant differences were observed between Tresiba and insulin detemir for the maternal safety endpoints (hypoglycaemia, pre-term delivery, pre-eclampsia, non-planned caesarean section and adverse events during the pregnancy). The majority of the adverse events reported in both groups were non-serious, mild in severity, unlikely related to the trial product and had the outcome &ldquo;recovered/resolved&rdquo;. No deaths were reported in the subjects who were randomised in the trial.</p><p>&nbsp;</p><p>No perinatal or neonatal death was reported. No clinically relevant differences were observed between Tresiba and insulin detemir for the pregnancy endpoints (early foetal death, presence of major abnormalities, neonatal hypoglycaemia, perinatal mortality, neonatal mortality, foetal macrosomia, large for gestational age, and adverse events in the infant during the 30 days after birth).</p><p>&nbsp;</p><p><strong>Table 8 Results from the open-label, randomised active controlled clinical trial in pregnant women with type 1 diabetes mellitus</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u><strong>Tresiba</strong></u></p></td><td style="vertical-align:top"><p><u><strong>Insulin detemir</strong></u></p></td></tr><tr><td style="vertical-align:top"><p><strong>Full Analysis Set for pregnant women (N)</strong></p></td><td style="vertical-align:top"><p>92</p></td><td style="vertical-align:top"><p>96</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HbA1c </strong>(%) <strong>at treatment baseline</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>6.73 (0.65)</p></td><td style="vertical-align:top"><p>6.56 (0.77)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HbA1c </strong>(%) <strong>at last planned visit prior to delivery</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>84</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>6.30 (0.70)</p></td><td style="vertical-align:top"><p>6.26 (0.73)</p></td></tr><tr><td style="vertical-align:top"><p>Estimated treatment difference</p></td><td colspan="2" style="vertical-align:top"><p><em>-0.11%-points [-0.31; 0.08]95%CI; p&lt;0.0001</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HbA1c &le; 6.0% - in-trial pregnancy period &ndash; treatment baseline</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of subjects</p></td><td style="vertical-align:top"><p>12.6</p></td><td style="vertical-align:top"><p>28.9</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HbA1c &le; 6.0% - in-trial pregnancy period- at last planned visit prior to delivery</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>84</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of subjects</p></td><td style="vertical-align:top"><p>42.9</p></td><td style="vertical-align:top"><p>36.9</p></td></tr><tr><td style="vertical-align:top"><p>Estimated odds ratio</p></td><td colspan="2" style="vertical-align:top"><p><em>1.95 [0.92; 4.17]95%CI, p = 0.0832</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HbA1c &le; 6.5% - in-trial pregnancy period &ndash; treatment baseline</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of subjects</p></td><td style="vertical-align:top"><p>39.1</p></td><td style="vertical-align:top"><p>45.6</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HbA1c &le; 6.5% - in-trial pregnancy period- at last planned visit prior to delivery</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>84</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of subjects</p></td><td style="vertical-align:top"><p>69.0</p></td><td style="vertical-align:top"><p>63.1</p></td></tr><tr><td style="vertical-align:top"><p>Estimated odds ratio</p></td><td colspan="2" style="vertical-align:top"><p><em>2.05 [0.97; 4.33]95%CI, p = 0.0617</em></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>FPG (mmol/L) at treatment baseline</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>8.15 (3.68)</p></td><td style="vertical-align:top"><p>7.64 (3.03)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>FPG (mmol/L) at last planned visit prior to delivery</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>82</p></td><td style="vertical-align:top"><p>83</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>6.17 (2.05)</p></td><td style="vertical-align:top"><p>6.79 (2.47)</p></td></tr><tr><td style="vertical-align:top"><p>Estimated treatment difference</p></td><td colspan="2" style="vertical-align:top"><p><em>-0.69 mmol/L [-1.42; 0.04]95%CI, p = 0.0652</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Average PPG (mmol/L) at treatment baseline</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>88</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>7.45 (2.02)</p></td><td style="vertical-align:top"><p>7.58 (2.23)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Average PPG (mmol/L) at last planned visit prior to delivery</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>74</p></td><td style="vertical-align:top"><p>70</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>7.37 (1.35)</p></td><td style="vertical-align:top"><p>6.96 (1.63)</p></td></tr><tr><td style="vertical-align:top"><p>Estimated treatment difference</p></td><td colspan="2" style="vertical-align:top"><p><em>0.44 mmol/L [-0.13; 1.00]95%CI, p = 0.1277</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Safety analysis set pregnant women &ndash; pregnancy period</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of subjects with at least one</p><p>hypoglycaemic episode</p></td><td style="vertical-align:top"><p>89 (97.8%)</p></td><td style="vertical-align:top"><p>91 (96.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Number of events</p></td><td style="vertical-align:top"><p>5431</p></td><td style="vertical-align:top"><p>5982</p></td></tr><tr><td style="vertical-align:top"><p>Rate per 100 years of exposure</p></td><td style="vertical-align:top"><p>11,844.9</p></td><td style="vertical-align:top"><p>13,401.2</p></td></tr></tbody></table><p>&nbsp;</p><p>The results from the EXPECT trial indicate that Tresiba is not associated with an excess risk of adverse pregnancy outcomes, when compared to insulin detemir, in women with pre-existing diabetes.</p><p>&nbsp;</p><p>In a prospective non-interventional post-authorisation safety study (EVOLVE), pregnant women with type 1 or type 2 diabetes exposed to insulin detemir (n=727) or other basal insulins (n=730) were monitored for adverse pregnancy outcomes. A subset of patients in this study were exposed to Tresiba (n=41). No safety concerns were observed for the subgroup treated with Tresiba.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of trials with Tresiba in:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neonates and infants from birth to less than 12 months of age with type 1 diabetes mellitus and children from birth to less than 10 years of age with type 2 diabetes mellitus on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>The efficacy and safety of Tresiba have been studied in a 1:1 randomised controlled clinical trial in children and adolescents with type 1 diabetes mellitus for a period of 26 weeks (n=350), followed by a 26-week extension period (n=280). Patients in the Tresiba arm included 43 children aged 1&ndash;5 years, 70 children aged 6&ndash;11 years and 61 adolescents aged 12&ndash;17 years. Tresiba dosed once daily showed similar reduction in HbA1c at week 52 and greater reduction in FPG from baseline versus the comparator insulin detemir dosed once or twice daily. This was achieved with 30% lower daily doses of Tresiba compared to insulin detemir. The rates (events per patient-year of exposure) of severe hypoglycaemia (ISPAD definition; 0.51 vs 0.33), confirmed hypoglycaemia (57.71 vs 54.05) and nocturnal confirmed hypoglycaemia (6.03 vs 7.60) were comparable with Tresiba versus insulin detemir. In both treatment arms, children aged 6-11 years had a numerically higher rate of confirmed hypoglycaemia than in the other age groups. A numerically higher rate of severe hypoglycaemia in children aged 6-11 years in the Tresiba arm was observed. The rate of hyperglycaemic episodes with ketosis was significantly lower for Tresiba versus insulin detemir, 0.68 and 1.09, respectively. No safety issues were identified with Tresiba with respect to adverse events and standard safety parameters. Antibody development was sparse and had no clinical impact. Efficacy and safety data for adolescent patients with type 2 diabetes mellitus have been extrapolated from data for adolescent and adult patients with type 1 diabetes mellitus and adult patients with type 2 diabetes mellitus. Results support the use of Tresiba in adolescent patients with type 2 diabetes mellitus.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After subcutaneous injection, soluble and stable multi-hexamers are formed creating a depot of insulin in the subcutaneous tissue. Insulin degludec monomers gradually separate from the multi-hexamers thus resulting in a slow and continuous delivery of insulin degludec into the circulation.</p><p>&nbsp;</p><p>Steady-state serum concentration is reached after 2&ndash;3 days of daily Tresiba administration.</p><p>&nbsp;</p><p>During a period of 24 hours with once-daily treatment, the exposure of insulin degludec was evenly distributed between the first and second 12 hours. The ratio between AUCIDeg,0-12h,SS and AUCIDeg,&tau;,SS was 0.5.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The affinity of insulin degludec to serum albumin corresponds to a plasma protein binding of &gt;99% in human plasma.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are inactive.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The half-life after subcutaneous administration of Tresiba is determined by the rate of absorption from the subcutaneous tissue. The half-life of Tresiba is approximately 25 hours independent of dose.</p><p>&nbsp;</p><p><u>Linearity</u></p><p>Dose proportionality in total exposure is observed after subcutaneous administration within the therapeutic dose range. In direct comparison, requirements for bioequivalence are met for Tresiba 100 units/mL and Tresiba 200 units/mL (based on AUCIDeg,&tau;,SS and Cmax,IDeg,SS).</p><p>&nbsp;</p><p><u>Gender</u></p><p>There is no gender difference in the pharmacokinetic properties of this medicinal product.</p><p>&nbsp;</p><p><u>Elderly, race, renal and hepatic impairment</u></p><p>There is no difference in the pharmacokinetics of insulin degludec between elderly and younger adult patients, between races or between healthy subjects and patients with renal or hepatic impairment.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Pharmacokinetic properties of insulin degludec in children (1-11 years) and adolescents (12-18 years) were at steady state comparable to those observed in adults with type 1 diabetes mellitus. Total exposure after a single dose was, however, higher in children and adolescents than in adults with type 1 diabetes mellitus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no safety concerns for humans based on studies of safety pharmacology, repeated dose toxicity, carcinogenic potential, and toxicity to reproduction.</p><p>&nbsp;</p><p>The ratio of mitogenic relative to metabolic potency for insulin degludec is comparable to that of human insulin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycerol</p><p>Metacresol</p><p>Phenol</p><p>Zinc acetate</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>This medicinal product must not be mixed with any other medicinal products. Substances added to Tresiba may cause degradation of insulin degludec.</p><p>Tresiba must not be added to infusion fluids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months.

Tresiba 100 units/mL solution for injection in pre-filled pen
After first opening or carried as a spare, the medicinal product may be stored for a maximum of
8 weeks. Do not store above 30°C. Can be stored in a refrigerator (2°C – 8°C). Keep the cap on the pen in order to protect from light.

Tresiba 200 units/mL solution for injection in pre-filled pen
After first opening or carried as a spare, the medicinal product may be stored for a maximum of
8 weeks. Do not store above 30°C. Can be stored in a refrigerator (2°C – 8°C). Keep the cap on the pen in order to protect from light.

Tresiba 100 units/mL solution for injection in cartridge
After first opening or carried as a spare, the medicinal product may be stored for a maximum of
8 weeks. Do not store above 30°C. Do not refrigerate. Keep cartridges in the outer carton in order to protect from light.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tresiba 100 units/mL solution for injection in pre-filled pen</u></p><p><em>Before first use:</em></p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep away from the freezing element.</p><p>Keep the cap on the pen in order to protect it from light.</p><p>&nbsp;</p><p><u>Tresiba 200 units/mL solution for injection in pre-filled pen</u></p><p><em>Before first use:</em></p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep away from the freezing element.</p><p>Keep the cap on the pen in order to protect it from light.</p><p>&nbsp;</p><p><u>Tresiba 100 units/mL solution for injection in cartridge</u></p><p><em>Before first use:</em></p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep away from the freezing element.</p><p>Keep cartridges in the outer carton in order to protect them from light.</p><p>&nbsp;</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tresiba 100 units/mL solution for injection in pre-filled pen</u></p><p>3 mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a laminate rubber sheet (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene.</p><p>&nbsp;</p><p>Pack sizes of 1 (with or without needles), 5 (without needles) and multipack containing 10 (2 packs of 5) (without needles) pre-filled pens.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><u>Tresiba 200 units/mL solution for injection in pre-filled pen</u></p><p>3 mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a laminate rubber sheet (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene.</p><p>&nbsp;</p><p>Pack sizes of 1 (with or without needles), 2 (without needles), 3 (without needles), 5 (without needles) and multipack containing 6 (2 packs of 3) (without needles) pre-filled pens.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><u>Tresiba 100 units/mL solution for injection in cartridge</u></p><p>3 mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a laminate rubber sheet (halobutyl/polyisoprene) in a carton.</p><p>&nbsp;</p><p>Pack sizes of 5 and 10 cartridges. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is for use by one person only. It must not be refilled. Tresiba must not be used if the solution does not appear clear and colourless. Tresiba which has been frozen must not be used.</p><p>A new needle must always be attached before each use. Needles must not be re-used. The patient should discard the needle after each injection.</p><p>&nbsp;</p><p>In the event of blocked needles, patients must follow the instructions described in the instructions for use accompanying the package leaflet.</p><p>&nbsp;</p><p>Any waste material should be disposed of in accordance with local requirements. For detailed instructions for use, see the package leaflet.</p><p>Tresiba in a pre-filled pen is available in two strengths. &ldquo;Tresiba 100 units/mL&rdquo; or &ldquo;Tresiba</p><p>200 units/mL&rdquo; is clearly marked on the pen label and packaging.</p><p>&nbsp;</p><p><u>Tresiba 100 units/mL solution for injection in pre-filled pen</u> Tresiba 100 units/mL packaging and label are light green.</p><p>The pre-filled pen (FlexTouch) is designed to be used with NovoFine/NovoTwist injection needles up to a length of 8 mm. It delivers 1&ndash;80 units in steps of 1 unit. Detailed instructions accompanying the pre-filled pen must be followed.</p><p>&nbsp;</p><p><u>Tresiba 200 units/mL solution for injection in pre-filled pen</u></p><p>Tresiba 200 units/mL packaging and label are dark green with striping with a red box highlighting the formulation strength.</p><p>The pre-filled pen (FlexTouch) is designed to be used with NovoFine/NovoTwist injection needles up to a length of 8 mm. It delivers 2&ndash;160 units in steps of 2 units. Detailed instructions accompanying the</p><p>&nbsp;</p><p>pre-filled pen must be followed.</p><p>&nbsp;</p><p><u>Tresiba 100 units/mL solution for injection in cartridge</u></p><p>The cartridge (Penfill) is designed to be used with Novo Nordisk delivery systems (durable devices for repeated use not included in the pack) and NovoFine/NovoTwist injection needles up to a length of</p><p>8 mm. Detailed instructions accompanying the delivery system must be followed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S 
Novo Allé
DK-2880 Bagsværd 
Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov-2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>